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Keep an open mind toward pneumonia. Our grandchildren will be interested and are likely to 
have as many differences of opinion regarding the disease as we have. 
 
 






Twenty-five percent of hospital infections occur in critical care patients. Up to 30% of these 
develop ventilator associated pneumonia, increasing length of stay, morbidity, mortality and 
cost. Causative bacteria are predominantly Gram-negative, and with increasing multidrug-
resistant strains, we must look towards non-antibiotic strategies in prevention and treatment. 
Probiotics are one option in this quest; however, efficacy and mechanisms of action are unclear. 
The randomised controlled trials of probiotics to date, have predominantly used Gram-positive 
bacteria and varied in their inclusion criteria, sample size and population studied, in addition to 
formula, dosing and route of administration. These studies have yielded conflicting results, 
however, there is some evidence that ventilator associated pneumonia can be prevented by 
probiotic treatment. 
 
This thesis demonstrates successful gastric colonisation by probiotic Escherichia coli Nissle 
1917 in ventilated patients. Trends toward dose-dependent incidence, and time to colonisation 
were observed, but these were not statistically significant. In the 15 millilitre treatment group, 
there was a significant reduction in the burden of pathogenic Gram-negative bacteria in gastric 
aspirates after 48 hours. Probiotic Escherichia coli Nissle 1917 can be safely administered to a 
selected group of critically ill patients. As a reduction in pathogenic Gram-negative gastric 
colonisation has been demonstrated, further study is warranted to determine if this leads to a 
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1.1 Infection in critical care 
There are at least 100,000 cases of hospital acquired infection (HAI) per year in England, 
causing around 5,000 deaths, and costing the UK NHS somewhere in the region of £1 billion 
each year (1). Patients in Intensive Care Units (ICUs) are a small subgroup of hospitalised 
patients, yet they account for approximately 25% of all hospital infections (2). HAI rates among 
ICU patients are 5-10 times higher than among general ward patients (2). Approximately 30% 
of ICU patients suffer from infection as a serious complication of critical illness (3), increasing 
ICU length of stay and incurring excess costs of £10,000 - £30,000 per patient. Furthermore, 
there is a relationship between the prevalence of ICU acquired infection and mortality (figure 
1.1)(4). 
Figure 1.1 Correlation between prevalence of ICU acquired infection and mortality rate 
by country (4) 
 3 
In addition to demonstrating the scale of the problem of ICU acquired infection, the European 
Prevalence of Infection in Intensive Care (EPIC) study also highlighted some interesting points 
about the geographical trends in infection rates across Europe. The prevalence of ICU acquired 
infection ranged from 10% in Switzerland to 32% in Italy. Of note, the mortality rate in Italy is 
similar to that in the UK yet the prevalence of infection in Italy is more than twice as high. This 
may reflect differences in patient selection and ICU practices between different countries. For 
example, the relatively low number of ICU beds in the UK compared to other European 
countries is likely to result in a more severely ill ICU population. 
ICU acquired (nosocomial) infection is defined as an infection that is not present or incubating 
when the patient is admitted to an intensive care unit (5). The time frame for diagnosis of an 
ICU acquired infection will thus clearly be dependent upon the incubation period of the specific 
infection; 48–72 hours after admission is generally deemed indicative of nosocomial, rather 
than community-acquired, infection. The peak of incidence of ICU acquired infection occurs 
around the fifth day after admission (6). The predominant risk factors for ICU acquired 
infection are length of ICU stay, requirement for mechanical ventilation, and the presence of 
central venous, pulmonary artery, and urinary catheters (4).  
Among ICU patients, the six most common sites of infection are pneumonia, bloodstream 
infections (including infective endocarditis), intravascular catheter-related sepsis, intra-





1.2 Ventilator associated pneumonia 
1.2.1 Overview 
Ventilator associated pneumonia (VAP) is a nosocomial pneumonia that develops more than 
48 hours after tracheal intubation and mechanical ventilation (8). VAP occurs because 
potentially pathogenic bacteria from the sinuses, oropharynx, subglottis and gastrointestinal 
(GI) tract gain access to the lower respiratory tract in the critically ill patient. This is facilitated 
by the presence of the tracheal tube (TT), which allows microaspiration of secretions and 
biofilm formation, by-passing the body’s natural defence mechanisms (9).  
 
Making a diagnosis of VAP is difficult due to its associated non-specific signs e.g. chest 
radiograph infiltrates, fever, leucocytosis and purulent respiratory secretions. The differential 
diagnosis includes pulmonary oedema, atelectasis, pulmonary embolism, ARDS and 
pulmonary haemorrhage. 
 
VAP is the most common HAI in the adult critical care environment. In the EPIC study, 
pneumonia and lower respiratory tract infections accounted for more than 50% of ICU acquired 
infections (4). Subsequently, in the Sepsis Occurrence in Acutely Ill Patients (SOAP) study, the 
respiratory tract was again found to be the predominant site of ICU acquired infection (10). 
 
The precise incidence of VAP is somewhat elusive and depends on the type of ICU population 
studied, the duration of mechanical ventilation and the diagnostic criteria used. Bearing this in 
mind, the evidence suggests that VAP occurs in 9-27% of mechanically ventilated patients, 





is also difficult to define, but it is clear that VAP makes a significant contribution to mortality, 
morbidity, length of ICU and hospital stay and financial cost (9). 
 
The diagnosis of VAP is made on a combination of clinical, radiological and microbiological 
criteria. However, there is still no consensus definition, as no combination of criteria offers 
enough diagnostic accuracy or confidence to justify their use in defining VAP. The commonly 
used ‘gold standard’ diagnosis of VAP is made using the American College of Chest Physicians 
(ACCP) clinical criteria and quantitative cultures of distal airways samples obtained by non-
bronchoscopic bronchoalveolar lavage (BAL) using a protected catheter. The ACCP clinical 
criteria require a new and persistent infiltrate on chest radiographs with two out of three 
supporting findings: fever (>38.5° C or <35.0° C), leucocytosis (white blood cells >10,000   
mm-3 or <3,000 mm-3) and/or purulent sputum (12). 
 
Hospital acquired infections in the critically ill population have been the focus of much 
attention in recent years, in particular, ventilator associated pneumonia. There is no doubt that 
VAP is a major cause of morbidity and mortality, with HAP and VAP together accounting for 
22% of hospital acquired infections (HAIs) (13). In addition, there is concern about the role of 
multi-drug resistant (MDR) organisms in their pathogenesis, combined with the 
‘indiscriminate’ use of broad-spectrum antibiotics.  Not only have clinical concerns been 
highlighted; these events also confer a financial burden to health care systems, with an episode 
of HAP increasing hospital stay by an average of 7-9 days and costing more than $40,000 per 








The main VAP scoring systems and definitions currently in use are the Clinical Pulmonary 
Infection Score (CPIS), the US Centers for Disease Control National Healthcare Safety 
Network (CDC-NHSN) definition and the Hospitals in Europe Link for Infection Control 
through Surveillance (HELICS) criteria. None of these systems are without the drawbacks of 
inter-individual variability of reporting and use of subjective clinical criteria; thus, the reported 
incidences of VAP vary according to the diagnostic criteria used. 
 
To complicate the ‘VAP’ issue, the terminology used in discussions about VAP is not 
straightforward and various definitions have been used in connection with respiratory HAIs. 
The term healthcare-associated pneumonia (HCAP) was used together with HAP and VAP in 
the 2005 American Thoracic Society Guidelines for the Management of Adults with Hospital-
acquired, Ventilator-associated, and Healthcare-associated Pneumonia (14). The thinking 
behind the use of the term, HCAP, was that this group of patients were at particular risk of 
developing infections with MDR pathogens by virtue of their contact with the healthcare 
environment – not only in the acute care setting but in a variety of community care 
environments. This would obviously dictate antibiotic treatment as such patients may not 
develop a straightforward community acquired pneumonia (CAP). Subsequent evidence has 
called this idea into question (15,16). Although interaction with healthcare environments may 
be a risk factor for acquiring infections with MDR organisms, many of these patients are not at 
high risk from these pathogens, with underlying patient characteristics playing an important 
role in the development of infection (15).  Therefore, in the 2016 guidelines (Management of 





Guidelines by the Infectious Diseases Society of America and the American Thoracic Society) 
the term HCAP has been removed (13). 
 
The Centers for Disease Control (CDC) 2008 document ‘Surveillance definition of health care–
associated infection’ was designed as an HAI surveillance tool and the pneumonia (PNEU) 
definitions used therein were not intended for the clinical classification of pneumonia or VAP 
(17). When they were applied to the diagnosis of VAP, they were shown to have good 
sensitivity and positive predictive value, but low specificity when compared with criteria that 
include microbiological results from bronchoscopy. The flow diagram for the adult pneumonia 
algorithm which was originally designed to be used as a data collection tool is shown in Figure 
1.2. 
 
Subsequently, in 2013, the National Healthcare Safety Network (NHSN), the CDC’s HAI 
surveillance system, revised the pneumonia (PNEU) definitions after convening a VAP 
Surveillance Definition Working Group (18). It was felt that the previous PNEU definitions 
were useful for internal quality improvement purposes and surveillance but were limited by 
their subjectivity and complexity. Therefore, the 2008 terminology and criteria were amended 
to have objective, reliable surveillance definitions for use in public reporting and for inter-







Figure 1.2 The Pneumonia Flow Diagram from the 2008 CDC/NHSN surveillance 
definition of health care–associated infection and criteria for specific types of infections 







It was highlighted, once again by the Working Group, that there is currently no valid, gold 
standard, reliable definition of VAP. Even the most widely used VAP definitions are neither 
sensitive nor specific. The Working Group therefore decided to develop a surveillance 
definition algorithm for detection of ventilator-associated events (VAEs). This algorithm was 
designed to detect a broad range of conditions and/or complications arising during the 
mechanical ventilation of adult patients (figure 1.3). It is from this algorithm that the new 
battery of terms, alluded to below, originated. The key differences which were brought about 
by this review are (18): -  
 
i. The use of VAE as the ‘catch-all’ surveillance term. 
ii. The introduction of a significant change with regard to timing. Previously, any 
pneumonia in a patient receiving mechanical ventilation was considered a VAP - even 
if this occurred within the first 24 hours of admission. For example, pneumonia 
developing from an episode of aspiration in a critically ill patient just prior to intubation 
could be considered a VAP. In the new surveillance algorithm, at least 48 hours of 
stability on a ventilator must be documented before a VAE can be considered.  
iii. An increase in positive end-expiratory pressure (PEEP) or fraction of inspired oxygen 
(FiO2) must be present for more than 2 days. It was envisaged that this would give 
greater validity to a VAE diagnosis.  
iv. The chest radiograph is now absent from the diagnostic protocol. With the wide 
variability in interpretation of new infiltrates in mechanically ventilated patients, the 
reliability and reproducibility of chest radiographs as a criterion for diagnosis of VAP 








Figure 1.3 Ventilator-associated events surveillance definition algorithm produced by the 







Interpretation of the literature is hampered by the variable use of the terms hospital acquired 
pneumonia (HAP) and VAP.  In the 2005 American Thoracic Society Guidelines, pneumonia 
was defined as the presence of a ‘new lung infiltrate plus clinical evidence that the infiltrate is 
of an infectious origin, including the new onset of fever, purulent secretions, leucocytosis, and 
worsening oxygenation’ (14). This definition continues to be used in the 2016 American 
Thoracic Society Guidelines.  Similarly, the terms HAP and VAP are still widely used and their 
definitions have also been upheld. HAP refers to a pneumonia that is not incubating at the time 
of hospital admission and occurring 48 hours or more after admission. VAP is ‘a pneumonia 
occurring >48 hours after endotracheal intubation’ (13). For clarity, they are regarded as 
separate entities, therefore avoiding expressions such as ‘ventilator associated HAP’.  
 
Other terms, such as ventilator associated events (VAE), including ventilator-associated 
conditions (VAC), infection-related ventilator-associated complications (IVAC) and possible 
or probable VAP, have now gained widespread use in the literature. The term ventilator 
associated complications (VAC) has been coined by US Centers for Disease Control and 
Prevention (CDC) as potential metric to assess the quality of care provided to ventilated patients 
(19). These terms may be useful from an epidemiological study perspective but do not 
necessarily aid classification from a clinical perspective and may confuse clinical study of these 
entities. Furthermore, the term VAC is now being used with two potential meanings; ventilator 
associated complications (19)  or as part of the CDC first tier definition, ventilator-associated 








1.2.3 Incidence and attributable mortality 
VAP is the most common HAI in adult critical care patients (10) and is undeniably an entity 
with which critical care physicians are familiar. However, the lack of a consensus definition for 
VAP remains a problem, as does the lack of a consensus on a gold standard diagnostic test or 
diagnostic criteria. This presents obvious difficulties in trying to present exact incidence data. 
To add to an already complicated situation which the American Thoracic Society have 
attempted to simplify in their 2016 guidelines, we are also presented with statements such as 
‘VAP contributes to approximately half of all cases of hospital-acquired pneumonia’ (20). 
 
Despite this, the US Institute of Healthcare Improvements identified ‘VAP’ as one of six areas 
to target in their 2006 ‘100,000 Lives’ Campaign (21). Specifically, this was to be approached 
using the ‘ventilator bundle’ in an attempt to tackle the problem using an evidence-based 
approach to modifiable risk factors. 
 
VAP is variably estimated to occur in 9-27% of all mechanically ventilated patients (14,22). In 
one US publication looking at VAP incidence, the estimated rate varied from 1.2 to 8.5 per 
1,000 ventilator days depending on the definition used (23).   
 
In Europe, the incidence is estimated to be 12.2 per 1000 ventilator days (24). Data is also 
available for Scotland where a VAP rate of 6.5 per 1000 ventilator days has been observed (25). 
This is markedly different to the data from Wales which reported a VAP incidence of 1.2-2.2 
per 1000 ventilator days (26).  There are no national data available for VAP rates in England 





investigation into episodes of ventilator-associated respiratory tract infection (VARTI) in 
Welsh ICUs during two study periods, each of 14 days duration, from 2012 – 2014.  
 
The reported rate of 1.2-2.2 per 1000 ventilator days was based on the use of the HELICS 
surveillance definitions over the 2009 – 2013 period. In the Pugh et al study of 282 patients 
who were invasively ventilated for 48 hours or more, 10 episodes of VAP were identified 
according to the HELICS definition. This equates to 4.2 per 1000 ventilator days and is clearly 
more in keeping, at least, with the Scottish data. Interestingly, the cases of HELICS-defined 
VAP represented less than a third of the VARTIs for which antibiotics where initiated during 
the study period. This was due to the fact that almost half of the VARTIs were treated with 
antibiotics without radiological evidence being sought. 
 
The VARTI estimate from the study by Pugh et al was 11.3%. This is in keeping with a figure 
of 12% from a point prevalence study of UK antimicrobial use (27). Although the study had 
some drawbacks in terms of size and relatively limited periods of data collection, it raises 
interesting points not only regarding VAP definitions but also about critical care practices in 
the UK. 
 
The concept of attributable mortality has gained popularity in recent years. Any nosocomial 
pneumonia or VAP occurs in patients who already possess a mortality risk associated with their 
underlying disease process. Therefore, the risk of death associated with the nosocomial 
pneumonia will be in addition to this. Attributable mortality is defined as total mortality minus 
the mortality associated with the underlying disease process (28). The attributable mortality 





physiology scores at the time of admission, being at greater risk (28,29).   Attributable mortality 
appears to be related to risk of dying due to increased length of ICU stay (29), however the 
relationship between VAP and mortality is not clear cut. 
 
1.2.4 Clinical criteria and scoring systems 
The differences in approach to the definitions and classification of VAP have come about in 
part due to the variation in diagnostic strategies applied. On one hand the ‘clinical’ strategy 
aims to achieve early, effective treatment of patients with VAP while the ‘microbiological’ 
approach emphasises certainty of diagnosis and the avoidance of overtreatment with antibiotics.   
The potential VAP patient on an ICU will undergo the routine clinical assessment which 
examines new or progressive infiltrates on the chest radiograph, coupled with two or more of 
the following – PaO2/FiO2 ratio, fever, leucocytosis or leucopoenia and purulent (or change in 
quality and/or quantity) of secretions.  This is regarded as a reliable group of criteria on which 
to commence empirical antibiotic therapy. Clearly, adopting fewer criteria will lead to greater 
sensitivity in the diagnosis of VAP at the expense of specificity, with a concomitant increased 
frequency of antibiotic therapy. Conversely, applying broader set of criteria before embarking 
upon therapy will lead to cases of pneumonia being missed which should otherwise have been 
treated. 
 
The disadvantage of the clinical approach is that it consistently leads to more antibiotic use 
compared to decisions made with the benefit of microbiological results. The clinical approach 
can even lead to non-infective processes, such as pulmonary oedema, atelectasis or pulmonary 






In 1991 Pugin et al developed the Clinical Pulmonary Infection Score (CPIS) in order to 
facilitate the diagnosis of VAP using clinical parameters (30). The system gives a score of 0–3 
for temperature, leucocytosis, PaO2/FiO2 ratio, chest radiography, tracheal secretions and 
culture of tracheal aspirate. The maximum score that can be obtained is 12, with a score >6 
being categorised as diagnostic of VAP (table 1.1). Drawbacks of the CPIS score are inter-
observer variability, particularly regarding interpretation of the tracheal secretions and chest 
radiographs, and inclusion of respiratory tract secretion microbiology data which may take up 
to 72 hours to yield a result.  This cut-off at a score of >6 was determined by correlation with 
quantitative bronchoscopic and non-bronchoscopic BAL specimens.  
 
 
Temperature (°C) ≥ 36.5 ≤ 38.4 
≥ 38.4 ≤ 38.9 




White blood count (cell μl-1) ≥ 4,000 ≤ 11,000 
< 4,000 > 11,000 
















PaO2/FiO2 (mmHg) > 240 without ARDS 
< 240 without ARDS 
0 
2 
Culture  < 10,000 bacteria or no growth 
> 10,000 bacteria 













In 1999 Fàbregas et al examined the cadavers of 25 patients who had undergone mechanical 
ventilation. Histological and quantitative microbiological testing was conducted on post 
mortem lung samples which demonstrated that CPIS had a sensitivity of 77% and a specificity 
of 42% (31). This study made a comparison with the Johansen Criteria and found these to have 
a sensitivity and specificity of 69% and 75% respectively. The Johansen Criteria, which are a 
rudimentary form of CPIS, include the presence of infiltrates on the chest radiograph and two 
of three clinical criteria (leucocytosis, purulent secretions or fever) (32). 
 
Other studies have been carried out looking at the diagnostic accuracy of the CPIS criteria and 
these have produced a wide range of results (sensitivity 72-89%, specificity 17-85%). These 
are summarised in Table 1.2 (33).  
 
Direct comparison of studies is hampered by variation in the diagnostic gold standard that is 
applied. Nevertheless, these results are markedly different to the sensitivity and specificity 
(93% and 96% respectively) reported by Pugin et al in the original study. 
 
Another interesting point about the original description of the CPIS criteria is the inclusion of 
the bacterial index as a standard for defining VAP. Bacterial index was defined as the sum of 
quantitative cultures (log CFU ml-1) of organisms obtained and an index >5 was used to define 
VAP. This is not a widely used indicator, nor is it used in other studies. Furthermore, in the 
study by Schurink et al, a bacterial index of >6 rather than >5 was applied for the diagnosis of 
VAP (34). In the same study, the diagnosis of VAP using the CPIS criteria by two different 
intensivists was examined and this demonstrated poor correlation (k=0.16), providing further 




















et al 1995(35) 
(n=38) 
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Luyt et al(38) 
(n=-201) CPIS>6 
BAL>104 CFU or 




CPIS>5 BAL>104 CFU 83 17 - - - - 
Miller et al(39) 
(n=292) NHSN BAL>10
5 CFU 84 69 83 70 - - 
 
Sens=sensitivity; Spec=specificity; PPV=positive predictive value; NPV=negative predictive value 
LR+ = negative likelihood ratio; LR- = negative likelihood ratio 
BAL=bronchoalveolar lavage; PTC=protected telescopic catheter; PSB=protected specimen brushing 
CFU=colony forming units 
 
Table 1.2 Table summarising studies examining the diagnostic accuracy of the CPIS and 





Fartoukh et al investigated the diagnostic accuracy of three modifications of the CPIS — the 
first omitting the microbiological component (not included here), the second using Gram stain 
of BAL fluid for the microbiological component, the third using PSB Gram stain for the 






As the original CPIS criteria had a prerequisite for microbiological data, they could not be used 
as a VAP screening tool. Modifications to CPIS were therefore proposed by Singh et al which 
used only the first 5 CPIS criteria, excluding the score for ‘culture of tracheal aspirate’ (40). 
This was in an attempt to devise a strategy to avoid prolonged use of unnecessary antimicrobial 
therapy. 
 
Another approach to improve the rather low sensitivity and specificity of CPIS was the addition 
of a Gram stain of deep respiratory tract culture (obtained from BAL or blind protected 
telescoping catheter sample), devised by Fartoukh et al (37).  With this method, the CPIS for 
confirmed VAP was significantly higher than the score in patients with unconfirmed VAP. 
 
The Hospitals in Europe Link for Infection Control through Surveillance (HELICS) criteria are 
used for surveillance of VAP in Europe (41). HELICS uses a similar set of criteria to that of 
CDC-NHSN with a combination of clinical, radiological and microbiological criteria. These 
are illustrated in tables 1.3. The microbiological criteria are subdivided in to 5 categories (PN1 
- 5) depending on the microbiological method used.  
 
Morris et al used paired samples from 53 patients and found that if a BAL-based diagnosis 
(PN1) was used in preference to quantitative endotracheal aspirates (ETA)(PN2), VAP rates 
would be 59% lower in their unit (42). The criteria also allow for a diagnosis of VAP to be 























Patients must fulfil radiological, systemic and pulmonary criteria to meet the HELICS 
definition of pneumonia. For Intubation associated pneumonia, an invasive respiratory device 
must have been present for at least part of the preceding 48 hours. 
 
1.2.5 Microbiological sampling and testing methods 
Histopathologically, VAP represents lung parenchymal inflammation which arises as a result 
of inoculation of bacteria into the airways, largely attributed to microaspiration of secretions 
which have accumulated around the tracheal tube (TT).  The composition of these secretions is 
variable and includes a microbiota of commensals and healthcare associated organisms, some 
of which may exhibit antibiotic resistance (44). 
 
On a microscopic level, ventilator associated respiratory tract infection may be anywhere on 
the spectrum of tracheobronchitis, peribronchial pneumonitis, through to bronchopneumonia, 
with the pneumonia itself being largely heterogenous in nature (45).  
 
As discussed previously, relying solely on the clinical signs which result from this 
inflammatory process leads to overdiagnosis of VAP. However, the best microbiological 
method for identifying the causative bacteria in VAP is uncertain, adding a further layer of 
complexity and controversy when making the diagnosis.  
 
Various invasive and non-invasive sampling techniques are used to obtain respiratory 
secretions, including tracheal aspirates (TA), protected specimen brushings (PSB), protected 






The samples obtained can be analysed quantitatively (with a threshold count of bacterial growth 
to differentiate between infection and colonisation of the bronchial tree), semi-quantitatively 
(subjective quantitative scoring method of bacterial load in a Gram stain sample or culture plate 
by a technician) or qualitatively (the binary presence or absence of pathogenic organisms in 
culture).  
 
The rationale for using quantitative cultures of respiratory secretions in suspected VAP patients 
is to differentiate the organisms causing infection (those with a higher concentration) from 
colonising organisms (those with lower concentration), in order to direct antibiotic therapy. 
However, there is no clear consensus on the use of quantitative versus qualitative cultures in 
this patient group. 
 
The bacterial concentration in lung tissue from a histopathologically confirmed pneumonia is 
≥104 CFU g-1 which corresponds to a bacterial concentration in respiratory secretions of ≥105 
CFU ml-1. A series of threshold levels can be established for the samples obtained using the 
different techniques described above (46) and these are illustrated in table 1.4. 
 
According to the NHSN definitions, VAP is deemed possible when microscopically purulent 
secretions are noted and probable when a quantitative culture of lower respiratory material is 
above a designated threshold described in the table. The clinical role for these remains 
uncertain, in particular samples obtained bronchoscopically. 
 
Klompas et al reviewed a number of studies looking at pulmonary secretions obtained by a 





histopathological samples alone, or in combination with post-mortem lung culture as a gold 
standard. The objective was to assess diagnostic accuracy of pulmonary secretion microbiology 
and the results of this comparison are shown in table 1.5. 
 
One should still bear in mind that even interpretation of histopathological samples is not without 
controversy. The microscopic appearance of these specimens is affected by the time between 
initial clinical suspicion of VAP and subsequent post-mortem analysis, during which time some 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Finding and source Gold standard Sens (%) Spec (%) LR+ (95%CI) LR- (95%CI) 
 
>50% neutrophils in BAL fluid 
Kirtland et al 
(n=39)(48) 
Histology 100 53 2.0 (1.4-3.0) 0.09 (0.01-1.4) 
 
Neutrophils with intracellular 
bacteria in BAL fluid 
Kirtland et al 
(n=39)(48) 
Histology 33 60 0.83 (0.3-2.3) 1.1 (0.64-1.9) 
Papazian et al 1997 
(n=28)(49) 
Histology 54 53 1.2 (0.55-2.4) 0.87 (0.41-1.8) 
Summary    1.0 (0.59-1.9) 1.0 (0.64-1.6) 
 
Positive gram stain 







74 2.1 (0.81-5.5)  0.60 (0.28-1.3) 




89 5.3 (1.3-22)  0.50 (0.24-1.0) 




100 18 (1.1-302)  0.56 (0.32-0.99) 
 
Culture - tracheo-bronchial 
aspirate >105 CFU ml-1 




56 95 11 (1.6-78.5)  
 
0.47 (0.28-0.79) 
Fabregas et al (36) Histology + 
culture 
69 92 8.3 (1.2-56.2)  0.34 (0.15-0.77) 
 
Summary     9.6 (2.4-38)  0.42 (0.27-0.67) 
 
Culture - BAL fluid >104 CFU ml-1 
Torres et al (50) Histology 50 
 
42 0.86 (0.44-1.7)  1.2 (0.53-2.7) 






95 10 (1.4-71.4)  0.53 (0.33-0.84) 
Kirtland et al (48) Histology 11 
 
80 0.56 (0.08-4.0) 1.1 (0.83-1.5) 




58 1.8 (0.89-3.8)  0.40 (0.13-1.2) 
Summary     1.4 (0.76-2.5)  0.78 (0.51-1.2) 
 
Sens = sensitivity; Spec = specificity; LR+ = negative likelihood ratio; LR- = negative likelihood ratio; BAL = 




Table 1.5 The diagnostic accuracy of pulmonary secretion microbiology as determined 
by comparison of invasive and non-invasive sampling techniques and quantitative and 







In the two studies that examined culture of blind tracheobronchial aspirate, using >105 CFU-
ml-1 as a threshold, the diagnosis of VAP was significantly increased. The utility of quantitative 
culture from BAL fluid was less definitive, with a summary positive likelihood ratio of only 
1.4 (0.76-2.5) compared to 9.6 (2.4-38) for blind tracheobronchial aspirate.  
 
Several randomised controlled trials (RCTs) have been carried out in an attempt to establish if 
the more invasive sampling techniques (e.g. BAL or PSB) confer any patient outcome benefit 
when compared to the less invasive methods such as TA. The RCTs by Ruiz et al and Sanchez-
Nieto et al (51,52) looked at quantitative invasive versus quantitative non-invasive sampling 
techniques. Quantitative invasive versus non-quantitative non-invasive techniques were dealt 
with in another three RCTs (53–55). Of these five RCTs, only the study by Fagon et al (54) 
demonstrated a significant reduction in mortality at 14 and 28 days in the invasive treatment 
arm. Subsequently, a Cochrane meta-analysis of these five studies showed that there was no 
significant difference in mortality, length of ICU stay or duration of mechanical ventilation 
between the invasive and non-invasive groups or the quantitative and qualitative groups (56). 
 
1.2.6 Summary 
The debate continues with regard to what constitutes best practice in the diagnosis of VAP. The 
decision to treat or not to treat a patient with potential VAP rests with the treating intensivist 
and, for the time being, this decision will be based on the clinical, radiological and 
microbiological information available. Bacterial presence in respiratory secretions, confirmed 
by Gram-stain or growth above a quantitative threshold lends weight to the diagnosis of VAP. 
However, clinicians should keep an open mind in these patients and if not improving after 48 






1.3 Prevention of ventilator associated pneumonia 
 
Ventilator associated pneumonia is a preventable condition and, as such, the incidence of VAP 
is deemed to be an important marker of quality of care on ICU (57). The development of VAP 
can be mitigated by a number of interventions which are aimed at reducing microaspiration and 
biofilm formation. These have been grouped together and are delivered as a ‘care bundle’.  
 
A care bundle, as defined by the Institute for Health Improvement (IHI) in the US, is ‘a 
structured way of improving the processes of care and patient outcomes: a small, 
straightforward set of (generally three to five) evidence-based practices that, when performed 
collectively and reliably, have been proven to improve patient outcomes’ (58). 
 
The original ventilator care bundle was an early example of the IHI care bundle methodology 
in the US. Care bundle methodology was adopted early in the UK, initially by the NHS 
Modernisation Agency and then via multiple agencies including the National Patient Safety 
Agency (NPSA). In 2007, ‘High Impact Intervention No 5 – Care bundle for ventilated patients’ 
was incorporated into the Department of Health (DOH) ‘Saving Lives: reducing infection, 
delivering clean and safe care’ campaign.  
 
1.3.1 Evidence-based care bundles 
The ventilator care ‘bundle’ or package of care was described by Resar et al in 2005 and looked 
at the effect of implementing this concept in 61 institutions from 2002 – 2004 (58). The results 
were striking and an average reduction in VAP of 44.5% was observed. This early bundle 
comprised ‘peptic ulcer disease prophylaxis, deep vein thrombosis prophylaxis, elevation of 





the interventions in the ‘100,000 Lives Campaign’ and subsequently in the ‘5 Million Lives 
Campaign’(59). 
 
The bundle concept was adopted and introduced in the UK by the, now defunct, NHS 
Modernisation Agency and subsequently the National Patient Safety Agency (NPSA). The 
2007 NHS campaign ‘Saving Lives: reducing infection, delivering clean and safe care’ cited 
the care bundle as a VAP prevention strategy in their ‘High Impact Intervention No 5’ (60). 
The 2007 document included daily sedation holds, elevation of the head of the bed, gastric ulcer 
prophylaxis and oral care.  
 
The bundle was subsequently updated in 2010 to include extended oral hygiene measures (using 
‘adequate strength’ antiseptics), subglottic aspiration and monitoring of TT cuff pressure (to 
maintain a cuff pressure of ≥ 20	and ≤ 30 cm H2O) (61). The six elements of the 
‘recommended good practice’ are described in table 1.6. 
 
An additional point, although one that was not included as an auditable component, was that 
‘ventilator tubing should be managed and positioned effectively to ensure condensate flows 
away from the patient and does not enter the patients’ airways’ (14). 
 
A single-centre before and after study by Morris et al examined the use of the original four high 
impact interventions when applied to an 18 bed Scottish ICU (62). Although there was only 
70% overall compliance with the bundle, they were able to demonstrate a reduction in VAP 





implementation. They were, however, unable to demonstrate a reduction in length of ICU stay 
or duration of mechanical ventilation.  
 
1. Elevation of the head of the bed 
• The head of the bed is elevated to 30-45° (unless contraindicated). 
2. Sedation level assessment  
• Unless the patient is awake and comfortable, sedation is reduced/held for assessment 
at least daily (unless contraindicated). 
3. Oral hygiene 
• The mouth is cleaned with chlorhexidine gluconate (≥1-2% gel or liquid) 6-hourly 
(as chlorhexidine can be inactivated by toothpaste, a gap of at least 2 hours should 
be left between its application and tooth brushing). 
• Teeth are brushed 12-hourly with standard toothpaste. 
4. Subglottic aspiration 
• A tracheal tube (endotracheal or tracheostomy) which has a subglottic secretion 
drainage port is used if the patient is expected to be intubated for >72 hrs. 
• Secretions are aspirated via the subglottic secretion port 1-2 hourly. 
5. Tracheal tube cuff pressure  
• Cuff pressure is measured 4-hourly, maintained between 20-30cm H2O (or 2cm H2O 
above peak inspiratory pressure) and recorded on the ICU chart. 
6. Stress ulcer prophylaxis  
• Stress ulcer prophylaxis is prescribed only to high-risk patients according to locally 
developed guidelines.  
• Prophylaxis is reviewed daily. 
 
Table 1.6 The six elements of the care process described in the 2010 Department of Health 







The current UK ventilator care bundle guidelines are published in the first edition of Guidelines 
for the Provision of Intensive Care Services (GPICS) (63). This document makes 
recommendations on measures that should be implemented to reduce the incidence of VAP.  
 
The current recommendations are:  
1. ICUs should have standardised systems to monitor VAP rates and antibiotic resistance 
patterns.  
2. Patients should be nursed in a semi-recumbent position (30o – 45o).  
3. Mechanically-ventilated patients should be tracheally intubated with an orotracheal tube 
(as opposed to nasotracheal tube which increases risk of maxillary sinusitis (64)) and 
cuff pressure maintained above 20 cmH2O.  
4. Subglottic suction tubes should be considered for use in patients who it is anticipated 
will be mechanically ventilated for more than 72 hours.  
5. Ventilator tubing and suction systems should only be changed if specifically indicated, 
such as by visible soiling, to avoid unnecessary changes.  
6. Stress ulcer prophylaxis should be used judiciously, and only in patients considered to 
be at high risk of upper gastrointestinal (GI) bleeding. 
 
These recommendations and the evidence on which they are based will now be discussed in 
more detail.  
 
1.3.2 VAP rate monitoring 
Audit forms part of the overall quality improvement strategy in ICU and should be targeted at 





compliance with ventilator care bundles and local VAP rates. This is recommended in GPICS 
as part of the framework to assist in the delivery of quality improvement in Critical Care (63). 
 
1.3.3 Patient positioning 
As discussed above, measures to prevent VAP are aimed at reducing microaspiration of gastric 
and oropharyngeal contents. It was demonstrated by Torres et al that there was significantly 
less aspiration of a technetium (Tc)-99m labelled sulphur colloid from the stomach, in patients 
nursed at 45º compared to those nursed in a supine position (65). Patient position in relation to 
VAP was also examined in an unblinded, randomised trial by Drakulovic et al (66). Bearing in 
mind the potential for bias, a significant reduction in VAP was demonstrated in the 45º group.  
 
In reality, it is unusual for patients to be nursed fully supine and so a further trial by van 
Nieuwenhoven et al compared 10º to 45º bed head elevations (67). The authors were unable to 
demonstrate a significant reduction in VAP, but the trial did illustrate what is known 
anecdotally – that achieving 45º elevation is difficult in practice. These studies demonstrate that 
there is an association between nursing ventilated ICU patients in the supine position and the 
development of VAP. However, the most beneficial degree of bed head elevation in the 
prevention of VAP is unclear, with the recommended minimum being 30º. 
 
1.3.4 Tracheal tube design 
A number of VAP prevention strategies have focused on the tracheal tube as this provides the 
conduit from the oropharynx to the bronchial tree. These include devices to control the pressure 
in the tracheal tube cuff, modifications which allow drainage of subglottic secretions, variations 





There are a number of devices currently on the market that aim to provide continuous control 
and monitoring of tracheal tube cuff pressure. These include devices such as Cuff Controller 
(VBM Medizintechnik GmbH), the Nosten® device (Leved, St-Maur, France), IntelliCuff® 
(Hamilton Medical) and the PressureEasy® Cuff Pressure Monitor (Smiths Medical).  
 
The optimal inflation pressure for the tracheal tube cuff is thought to be 20–30 cm H2O. 
Pressures below 20 cm H2O permit passage of secretions from the oropharynx into the trachea 
and pressures above 30 cm H2O cause injury to the tracheal mucosa by compromising the 
microcirculation (68). The paper by Rello et al is frequently cited regarding the potential 
complications of inadequate tracheal tube cuff pressure (69). In this study, there was a trend 
towards higher risk of VAP (RR = 2.57; 95% CI = 0.78 to 8.03) among patients whose cuff 
pressures were persistently less than 20 cm H2O.  Rello et al concluded that leakage of colonised 
sub-glottic secretions around the cuff was the most important risk factor for VAP within the 
first 8 days of mechanical ventilation. 
 
In a study of 122 patients, the Nosten® device was found to reduce the rate of microaspiration 
as defined by a reduction in pepsin found in tracheal secretions (18% vs 46%; P=0.002; OR 
[95% confidence interval], 0.25 [0.11-0.59]). Reduced bacterial concentration in tracheal 
aspirates (mean ± SD 1.6 ± 2.4 vs 3.1 ± 3.7 log10 CFU ml-1, P=0.014), and a reduced VAP rate 
(9.8 vs 26.2%; P=0.032) were also demonstrated as secondary outcomes (70). 
 
Valencia et al also looked at the maintenance of tracheal tube cuff pressure with an unspecified 
mechanical device in 142 patients (71). Cuff pressures were maintained in the target range 80% 





treatment group compared to 45.3% in the control group (P=0.001). A statistically significant 
difference in the VAP rate between the two groups was not demonstrated, although this is not 
surprising given the size of the study. 
 
The description above gives a rather simplistic view of cuff pressure and micro-aspiration. 
Control of cuff pressure is important, but it will only reduce, not completely eliminate, the 
unwanted flux of oropharyngeal and gastric secretions into the bronchial tree. The situation is 
not a static one, with a simple air-filled cushion forming a barrier around the tracheal tube. 
Instead the situation is dynamic, with constant changes in cuff pressure and the cuff-trachea 
interface brought about by coughing, movement and nursing interventions (68).  
 
Although mechanical devices may deliver a constant pressure, they may not afford a constant 
seal. It has been suggested that varying cuff pressure with inspiration and expiration may, in 
fact, be more effective than maintaining a constant cuff pressure. This was highlighted in a 
small study (n=10) of porcine models (72). This study also appeared to show that dynamic cuff 
pressure modulation might reduce the incidence of tracheal injury – although the model applied 
a period of hypoxic ventilation, which could itself predispose the tracheal mucosa to injury. 
 
The cuff of the modern tracheal tube is of a high-volume/low-pressure (HVLP) design, made 
of pliable medical grade polyvinylchloride (PVC), which forms to the airway as it is inflated. 
This is in contrast to the older high-pressure/low-volume (HPLV) cuff that could cause 






In order for the HVLP cuff to function correctly, it must have a deflated diameter greater than 
that of the trachea into which it will be inserted. This is to allow some slack in the cuff wall so 
that there is no tension when the cuff is inflated (73). Hence, all the intra-cuff pressure is 
transmitted to the tracheal wall allowing direct pressure measurement and monitoring.  
 
Unfortunately, even when inflated correctly, these cuffs allow some degree of aspiration to 
occur. The reason for this ongoing risk of aspiration, despite an appropriately inflated HVLP 
cuff, is the presence of microchannels. Microchannels exist because these cuffs will not be fully 
distended even when inflated to the recommended pressure. Patient and TT movement in 
addition to anatomical variations may exacerbate the passage of secretions via these 
microchannels (figure 1.4) (68).  
 
In this static depiction, the cuff creases gradually become smaller to form a proximal sealing 
band. In practice this is not the case due to patient and TT movement and anatomical variation. 
 
The risk of aspiration is reduced by having TT cuffs with thinner cuff walls or by completely 




























Figure 1.5 Model illustrating the effect of a reduction in the size of TT microchannels (74) 
 
The first five images are of HVLP cuffs of reducing thickness from left to right. The channel 
folds increase in size with thickness of cuff material, hence the amount of ink bypassing he cuff 
reduces from image one to image five. The sixth image is a silicone Lotrach® cuff, in which 
there is no leak as there are no folds. 
 
Other modifications to TT design have been proposed and implemented, such as silver-coating. 
Silver-coated TTs slowly release silver cations, which are known to have an antimicrobial 
effect. However, there is insufficient evidence at present to recommend their use outside clinical 
trials (75). 
 
1.3.5 Management of secretions  
Secretions containing potential pathogens pool in the area above the TT cuff and the true vocal 
cords. These may pass into the bronchial tree via the microchannels described above or at the 





specifically designed TTs (and tracheostomy tubes) are available that permit drainage of these 
‘subglottic’ secretions (9).   
 
Three meta-analyses have examined the role of subglottic secretion drainage (SSD) in ICU 
patients, all of which gave a signal towards a reduction in VAP (9). In a subsequent RCT of 
352 patients, SSD resulted in a reduction in the rate of microbiologically confirmed VAP (9.6 
vs 19.8 of 1,000 ventilatory days (p=0.0076)) and a significant reduction in the total number of 
antibiotic days (76). SSD is therefore suggested in patients who are likely to be mechanically 
ventilated for more than 72 hours. 
 
1.3.6 Timing of ventilator circuit changes 
Frequent ventilator circuit changes are thought to be a risk factor for VAP (77). This is due to 
the risk of introducing contaminated secretions or condensate to the patient via the TT by 
unnecessary manipulation of the tubing.  However, in two RCTs (which used different methods 
of humidification) routine seven-day tubing changes were compared to no routine changes 
(78,79). No significant differences in VAP rates were demonstrated between the two-trial arms 
in either trial. 
 
1.3.7 Stress ulcer prophylaxis 
Stress ulcer prophylaxis has traditionally formed part of the ventilator care bundle, however, 
pharmacologically reducing the acidic environment of the stomach risks promoting 






The use of proton pump inhibitors (PPI) is widespread in ICU despite the relatively low 
incidence of GI bleeding (81). Maclaren et al carried out an observational study of 35,312 
ventilated ICU patients receiving PPI or H2 receptor blockers (H2RA). PPI use was associated 
with more GI bleeding compared to H2RA (5.9% vs 2.1%), more VAP (38.6% vs 27%) and 
more Clostridium difficile infection (3.8% vs 2.2%) (82). 
 
Hence the GPICS recommendation state that stress ulcer prophylaxis should only be used in 
patients thought to be at high risk of upper GI bleeding (9). 
 
1.3.8 Oral chlorhexidine 
The recommendation for the use of oral chlorhexidine to decontaminate the oropharynx has 
been removed from the most recent guidelines. It is no longer recommended outside of cardiac 
ICU by the Intensive Care Society (ICS) or by the National Institute for Health and Care 
Excellence (NICE) (9).  
 
The previous recommendation for the use of chlorhexidine had been based on the results of two 
large meta-analyses which showed a reduction in VAP in the treatment groups (83,84). These 
meta-analyses included both general and cardiac ICU patients and a subsequent meta-analysis 
by Klompas et al demonstrated that the VAP reduction was not significant in the general ICU 
patients. Furthermore, there was a non-significant trend towards increased mortality in this 
group (85).  
 
In a further meta-analysis of GI decontamination practices, the use of oral chlorhexidine was 





compared to selective decontamination of the digestive tract (SDD) and selective oral 
decontamination (SOD) (86). 
  
1.3.9 Sedation practices 
Studies looking at ICU sedation practices tend to focus on duration of mechanical ventilation 
and length of ICU stay. However, there is some evidence that sedation holds (or daily 
interruption of sedation (DSI)) may reduce VAEs (87). As DSIs are associated with a reduction 
in duration of mechanical ventilation, this follows suit (9). intubation and mechanical 
ventilation predispose patients to VAP, hence, reducing the duration of mechanical ventilation 
should reduce the time they are at risk for developing VAP. 
 
Although DSI is not in the current GPICS recommendations for the prevention of VAP, there 
is sufficient evidence to support the implementation of DSI to prevent over-sedation and earlier 
liberation from mechanical ventilation. 
 
1.4 Emergence of resistant organisms in critical care 
Jean-Louis Vincent’s review article, published in Lancet 2003, provides a coherent statement 
regarding the pathophysiology of ICU acquired infection (3). ‘The development of ICU-
acquired infection is dependent on two key pathophysiological factors: decreased host defences 
and colonisation by pathogenic, or potentially pathogenic, bacteria. Although these two factors 








1.4.1 Reduced host defences 
Critical illness is associated with decreased host immune defence making this patient group 
more susceptible to nosocomial infection. Obviously, the administration of immunosuppressive 
drugs can contribute to this state, however, critical illness per se and mechanical ventilation are 
likely to have a detrimental effect on a patient’s immunocompetence.   
 
Morris et al have demonstrated neutrophil dysfunction and impaired phagocytosis in 
mechanically ventilated patients in whom there was a high clinical suspicion of VAP. They 
found significantly reduced phagocytic activity in these patients due to overexpression of the 
inflammatory anaphylatoxin C5a (88). Excess C5a is known to cause neutrophil dysfunction 
and this appears to precede, rather than occur as a result of, nosocomial infection (89) This is 
relevant to the ICU population as they are highly susceptible to HAIs and neutrophil 
dysfunction may play a role in their relative immunosuppression. 
 
Immunosuppression due to release of mediators such as interleukin 10 and interleukin-1-
receptor antagonist has also been demonstrated. If significant and prolonged, this acquired 
immunodeficiency state has been referred to as ‘immunoparalysis’. It is associated with an 
increased risk of infection-related complications, therefore placing such individuals in a 
particularly high-risk group for nosocomial infection (90).  
 
Immune defence also includes mechanical host-defence mechanisms; for example, coughing, 
sneezing, saliva production and mucociliary clearance are all important in the prevention of 





bypasses these protective mechanisms hence reducing local defences and predisposing to 
respiratory tract infection in mechanically ventilated patients. 
 
1.4.2 Colonisation by pathogenic bacteria 
Colonisation is the phenomenon of active bacterial growth on a body surface without the 
bacterial growth leading to immune response and infection. Colonisation is, however, an 
essential step in the development of infection. The bacteria in question may arise from the 
normal microbiological flora of the individual or they may have been introduced by another 
mechanism. 
 
It is common for ICU patients to be colonised by a variety of bacterial species. This occurs for 
a number of reasons including impaired host defences, the high intensity of antimicrobial use 
and the presence of invasive devices, e.g. catheters, that bypass normal protective mechanisms 
and act as a nidus for colonisation by microorganisms (3). 
 
Endogenous colonisation occurs when the colonising organism arises from the host’s own 
microbiota (92). Antibiotic use exerts selective pressure on patients’ normal microbiological 
flora, modifying it to promote potential pathogenic colonisers. This selective pressure will 
depend not only on the duration of antibiotic therapy but on the choice of agent. Exogenous 
colonisation is said to occur if the organism is acquired from the hospital environment or by 
cross-infection from another host (92). This occurs due to cross-transmission via direct contact, 






The efficiency of intestinal barrier function is demonstrated by the fact that the faecal bacterial 
concentration approaches 1012 organisms ml-1 in the caecum, while tissues one cell deep to the 
intact intestinal mucosa are usually sterile (93). In contrast to the large bowel, the stomach, 
duodenum and jejunum have a relative paucity of bacteria (103 to 104 organisms ml-1). The 
presence of enteric organisms in gastric aspirates is therefore abnormal and represents gastric 
colonisation. In the context of critical illness, this colonisation is the result of bacterial 
overgrowth in the proximal gastro intestinal tract (93).  
 
Increased adherence of microorganisms may also play an important role in colonisation of the 
critically ill patient. There are a number of reasons why this may occur: increased bacterial 
adherence to the oral and respiratory tract mucosa of the invasively ventilated patient is 
facilitated by reduced mucosal immunoglobin A production and increased protease production; 
exposure of, or trauma to mucous membranes; increased airway pH; and increased numbers of 
airway receptors for bacteria due to acute illness and antimicrobial use (94). 
 
Microbial adherence factors (adhesins) can exists as polypeptides or polysaccharides. Adhesin-
receptor interactions are important in defining the bacterial population found on any particular 
surface, with the apparent predilection of certain microorganisms for a particular host tissue, 
determined partly by the adhesin-receptor interaction on host cell surfaces (95). Changes in 
adhesins associated with antibiotic-resistant organisms, or in the host-adhesin interaction, may 







The genetic makeup of bacterial genomes is subject to rapid and dramatic change through a 
variety of processes collectively referred to as ‘horizontal gene transfer’. This flux plays a major 
role in the molecular evolution of novel bacterial pathogens.  
 
Horizontal gene transfer refers to the incorporation of genetic elements transferred from a donor 
organism directly into the genome of the recipient organism, where they form genomic islands. 
Genomic islands may contain large blocks of virulence determinants (adhesins, invasins, toxins, 
protein secretion systems, antibiotic resistance mechanisms), and thus are referred to as 
pathogenicity islands (97). 
 
For example, Pseudomonas aeruginosa has an array of virulence factors. The main adhesins 
are flagella and type 4 pili which are capable of binding to the host epithelial gangliosides, 
asialoGM1 and asialoGM2. As with lipopolysaccharide, these surface appendages are highly 
inflammatory. Once contact with the host epithelium has taken place, the T3SS (Type 3 
Secretion System) can be activated. This system enables direct injection of cytotoxins into the 
host cell (98). 
 
The most common reservoirs for nosocomial colonisers are the oropharynx, the gastrointestinal 
tract and the urinary tract (99). The oropharynx and gastrointestinal tract are most relevant with 
regard to VAP. Due to the alterations in host defences and the resulting changes in mucosal 
bacterial adherence discussed above, the oropharynx rapidly becomes colonised with aerobic 
Gram-negative bacteria. The resulting microaspiration of these contaminated oropharyngeal 






1.4.3 Gram-negative infection: a new threat  
There is now a major emphasis on infection control and prevention in UK hospitals. This has 
become a key quality improvement and patient safety issue in ICU. Government initiatives such 
as the Health Care Improvement’s 100,000 Lives Programme in the United States have also 
made an impact in the UK, with emphasis now placed on reductions in VAP and catheter-
related blood stream infections (101). Rates of ICU acquired infection are regarded as a quality 
marker and in the US rates of infection will even influence healthcare reimbursement. 
  
ICU acquired infection continues to be a major concern for trusts throughout the UK and the 
rest of the world. There has been a reduction in UK MRSA transmission and infection in recent 
years, linked to the mandatory MRSA bacteraemia surveillance scheme (102). However, the 
increasing prevalence of infection and sepsis caused by Gram-negative bacteria in critically ill 
adults is a major concern. The International Study of the Prevalence and Outcomes of Infection 
in Intensive Care Units (EPIC II) in 2007 found that Gram-negative bacteria were the 
predominant cause of infection accounting for 62% of culture-positive cases. Gram-positive 
organisms and fungi were isolated in 47% and 19% of cases respectively (103). More recently, 
Morrow et al (104) reported a 10% higher incidence of VAP with Gram-negative organisms 
than Gram-positive (22.8% vs 12.8%) in their own ICU (Creighton University School of 
Medicine, Omaha, Nebraska). Prevention of Gram-negative infection is therefore likely to 
become a focus for improving ICU outcomes in the future.  
 
Despite the widespread discussion about importance of VAP and other HAI’s, it is 





in the UK as a whole. VAP surveillance data is collected in Scotland and Wales and published 
findings and limitations are discussed further in section 1.2.3. 
 
It is encouraging, however, to see the development of the Infection in Critical Care Quality 
Improvement Programme (ICCQIP) (105). This is a collaboration between various 
organisations covering adult, paediatric and neonatal intensive acre, microbiology, infection 
control and Public Health England. Participation in this surveillance system is voluntary but is 
being offered to all acute Trusts in England. The initial focus has been on blood stream 
infections, but in time this will be rolled out to include other ICU-related HAI’s. 
 
The ICCQIP Collaboration also highlights the importance of multi-resistant Gram-negative 
bacteria and their importance for critically ill patients of all ages, mirroring the emphasis placed 
in this thesis (105). However, that is not to underestimate the importance of Gram-positive 
organisms in ICU-related infection and VAP. Again, UK specific data on this is lacking, but 
Hunter cites the distribution of organisms isolated from cases of VAP by bronchoscopic 
techniques from 24 studies which include 1689 VAP episodes (11). Approximately 34% of 
VAP episodes were caused by Gram-positive organisms, predominantly Staphylococci and 
Streptococci. In late onset VAP, the Gram-positive culprits are more likely to be MDR 
organisms e.g. MRSA.  
  
1.4.4 Multiple drug resistance in critical care 
In addition to the increasing prevalence of Gram-negative infections, a major challenge for 
healthcare professionals is the emergence of multi-drug resistant (MDR) Gram-negative 





beta-lactamase 1 (NDM-1) (106). The number of antibiotics available to treat such infections 
is limited and, paradoxically, research into new antibiotics and novel mechanisms of action has 
been decreasing. This has been attributed to high costs for development and a poor return on 
investments (107). 
 
The rise of MDR bacteria is most commonly attributed to the widespread use of broad-spectrum 
antibiotics. This is of particular relevance to ICU with over 60% of all ICU patients receiving 
antibiotics during their admission (108). However, the emergence and transmission of MDR 
organisms is more complicated, with the recognition that some antibiotics appear to carry a 
higher risk of promoting antimicrobial resistance than others e.g. third-generation 
cephalosporins, vancomycin, imipenem, and intravenous fluoroquinolones (109).  
 
Bonten and Mascini have described four main methods of emergence and spread of MDR 
organisms, outlined below (110):  
1. Induction of resistant strains – Development of resistant bacteria in response to 
antimicrobial treatment. 
2. Selection of resistant strains – Treatment with antimicrobials leading to selection of pre-
existing resistant organisms. 
3. Introduction of resistant strains – This can occur from the community reservoir, or via 
carriers or vectors (healthcare workers). 
4. Dissemination of resistant strains – Spread facilitated by suboptimal infection control. 
 
Infection control measures, such as hand washing, are important in controlling nosocomial 
infection, but these have only been partially successful in preventing the increase in incidence 
of drug-resistant bacterial strains both nationally and worldwide. In a Vietnamese study by 





washing and antibiotic cycling, was highly effective in reducing the prevalence of MRSA, but 
not of MDR Gram-negative microorganisms (111). This study was carried out in an infectious 
diseases hospital tetanus ICU. The reduction in MRSA is likely to reflect differences in the 
predominant acquisition routes between MRSA and GNB. The MRSA colonisation was largely 
via the exogenous route and was easily controlled by simple infection control interventions. It 
is unclear why these interventions did not result in a concomitant reduction in MDR GNB, but 
may reflect the high carriage rates of these bacteria in the local community, where 
Enterobacteriaceae resistant to third-generation cephalosporins and/or gentamicin were present 
in stool samples from up to 90% of healthy people (111). 
  
The focus of therapeutic interventions to date has largely been on treatment after sepsis has 
become established (112–114). Despite over three decades of intense research no silver bullet 
has yet been identified, although agents aimed at reducing the impact of sepsis have come and 
gone, e.g. activated protein C, without any clear evidence of outcome benefit (115); 
preventative measures therefore remain vitally important. 
   
In the absence of universally effective pharmacological treatments, alternative strategies aimed 
at preventing the development of ICU-acquired infection have been sought. Ventilator care 
bundles target modifiable risk factors for colonisation and aspiration, but despite having had a 
substantial impact on infection rates have not eliminated VAP.  
 
Selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination 
(SOD) with antibiotics are strategies that have been shown to significantly reduce the 





controlled trial (116) and several meta-analyses (117,118). Selective decontamination is 
effective as it reduces the presence of potentially pathogenic bacteria in the intestinal tract.  
 
However, Oostdijk et al demonstrated a statistically significant increase in intestinal 
colonisation with Gram-negative bacteria resistant to ceftazidime, tobramycin or ciprofloxacin 
during ICU stay and after ICU discharge (P <0.05) (119). These concerns were borne out by a 
large-cluster, randomised cross-over trial of selective decontamination of the digestive tract that 
showed a marked increase resistance to ceftazidime in faecal Enterobacteriaceae, together with 
a small but significant increase in bacterial resistance from the respiratory tract (120). In a 
previous trial, the use of cefotaxime as part of selective decontamination of the digestive tract 
regime was found to select for an outbreak of extended-spectrum β-lactamase-producing E. coli 
and Klebsiella pneumonia (121). Therefore, despite clear evidence of effectiveness, concerns 
regarding the negative consequences of antibiotic overuse and bacterial resistance have limited 
the widespread uptake of SDD and SOD (122). 
 
New antimicrobial agents are in limited supply. In 2010 an EU-US taskforce called for a 
commitment to the development of 10 new antibacterial agents by 2020 (The 10 × '20 Initiative: 
Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020) (123). This 
will require a substantial financial investment and will need to be sustained in the long-term, as 
continued antibiotic use will maintain the pressure on organisms to evolve new resistant strains. 
Therefore, the identification of an alternative method for reducing colonisation with Gram-








1.5.1 Probiotics, prebiotics and synbiotics 
Probiotics are defined as ‘live microorganisms that confer a health benefit on the host when 
administered in adequate amounts’ (124). Prebiotics are non-digestible food components that 
stimulate the growth and/or activity of bacteria in the digestive tract in ways that may be 
beneficial to health (125). Synbiotics are a combination of probiotics and prebiotics. There has 
been an explosion of interest in probiotics and their potential health benefits since 2000, with 
initial attention focusing on the gastrointestinal tract. 
 
1.5.2 Probiotics in critical care 
During an episode of critical illness, a number of significant changes occur in the microbiota 
of the human gut. These changes occur due to alterations in the stress hormone profile, 
impairment of blood supply to the gut, immunosuppression, antibiotic use and nutrient 
deficiency (126). In experimental models, these changes have been shown to occur within 6 to 
8 hours, with endogenous Lactobacillus strains being replaced by pathogenic bacteria (127). 
This change can lead to a breakdown in the intestinal barrier function and is likely to play a 
significant role in the pathogenesis of the multiple organ dysfunction syndrome (MODS) 
(128,129).  
 
Redressing this balance and exploiting the beneficial effects of probiotic bacteria is 
understandably an area of considerable interest. However, the mechanisms by which these 
microorganisms exert their effects are various and depend upon the dose used, the route(s) of 
administration and the dosing frequency (130). Furthermore, a number of these effects are strain 





are commonly used as probiotics. Campana et al demonstrated that individual LAB showed 
strain-specific abilities to reduce the invasion of intestinal pathogens e.g. by antimicrobial 
activity, co-aggregation with pathogens and adherence (131). 
 
The human intestine is home to hundreds of species of bacteria, archaea and eukarya, many of 
which are non-culturable but can now be identified using metagenomic techniques. The 
bacterial load tends to be highest in the large intestine (up to 1011 CFU g-1), and while the 
healthy human gut is dominated by Bacteroides, Firmicutes and Actinobacteria, each individual 
has their own distinct stool bacterial composition determined by environmental and genetic 
factors. This bacterial profile remains relatively constant over time unless altered by disease 
state or antibacterial treatment (132,133).  
 
Culture-based and molecular detection methods have demonstrated that it is possible to 
significantly alter the composition of gut flora in adults and infants by treatment with probiotics. 
Sepp et al treated 15 neonates with Lactobacillus rhamnosus GG for their first two weeks of 
life. They found that L. rhamnosus GG persisted for 1 month in eight of these neonates. There 
were also significant differences in the bacterial composition of the stool in the probiotic 
treatment compared with the control group, with increased numbers of coliforms, Lactobacillus 
and Bifidobacterium species (134).  
 
Benno et al demonstrated a statistically significant increase in bifidobacteria in adults treated 
with L. rhamnosus GG for a four-week period. They also found an increase in Lactobacilli and 





faecal profiling, they tend to reflect the large bowel bacterial composition with little information 
being available on the small bowel effects of probiotics. 
 
1.5.3 Mechanisms of action of probiotics 
Much of the information available on the mechanisms of action of probiotics has been obtained 
from animal work and in vitro studies; hence we must be careful in extrapolating this to humans. 
What is clear, however, is that there are multiple mechanisms by which different probiotic 
bacteria exert their effects. These effects may vary with the probiotic strain and population 
studied. Table 1.7 summarises the main mechanisms by which probiotics exert their effects, 
and table 1.8 presents details of commonly used probiotic preparations. 
 
Probiotics may alter the local environment within the lumen of the gut, producing antimicrobial 
effects on pathogenic organisms. Lactic acid and acetic acid producing probiotics reduce the 
luminal pH resulting in an unfavourable milieu for pathogens. This has been demonstrated in 
vitro, with pathogen growth being reduced in a pH-dependent manner by Lactobacillus species 
(136). Venturi et al demonstrated a significant luminal pH reduction, in vivo, in ulcerative 
colitis patients treated with the probiotic mixture VSL#3 (137). This may be a factor in 
maintaining remission in ulcerative colitis patients. 
 
Probiotics can also exert a direct antimicrobial effect via the production of bacteriocins. 
Bacteriocins are proteins produced by bacteria that inhibit the growth and virulence of other 
pathogenic bacteria. Probiotic bacteria which are deficient in the bacteriocin gene have 
diminished probiotic activity. This was demonstrated in a murine model where a mutant form 





monocytogenes (138). A wide variety of bacteriocins are recognised, and their spectrum of 
action ranges from antagonism of similar bacterial strains to the inhibition of a wide range of 
Gram-positives, Gram-negatives, yeasts and moulds (139). One such example of a broad-
spectrum bacteriocin is that produced by a subspecies of L. salivarius. The ABP-118 bacteriocin 
inhibits growth of Bacillus, Staphylococcus, Enterococcus, Listeria and Salmonella species. 
(140). 
 
Bacteria communicate with each other using a mechanism known as quorum sensing. This 
involves the production and secretion of signalling molecules known as autoinducers. In their 
in vitro study, Medellin-Peña et al demonstrated that Lactobacillus acidophilus La-5 secretes 
molecules that disrupt this inter-bacterial communication, reducing expression of virulence-
related genes by Escherichia coli O157:H7 (141). 
 
It has also been demonstrated that probiotics can enhance intestinal barrier function. Intestinal 
barrier function is complex, and its control involves cellular stability at a cytoskeletal and tight 
junction level, as well as mucus, chloride and water secretion. Probiotics have been shown to 
exert an effect, in vitro and in vivo, via these mechanisms (130). For example, Lactobacillus 
plantarum 299v can enhance mucus production and secretion in human intestinal epithelial 
cells (142). The probiotic strain Escherichia coli Nissle 1917 appears to enhance mucosal 
barrier function by production of human β-defensin 2 (139). It has also been demonstrated in 
vitro, that E. coli Nissle can reduce adhesion and invasion of intestinal epithelial cells by an 














Production of lactic acid and acetic 
acid reduces luminal pH resulting 
in unfavourable milieu for 
pathogens 
 
Lactobacillus spp.: pH-dependent reduction in 
pathogen growth (136) 
VSL#3: in vivo luminal pH reduction in ulcerative 






Bacteriocins are proteins produced 
by bacteria that inhibit the growth 
and virulence of other 
microorganisms. The may be 
narrow spectrum (inhibit related 
bacterial strains) or broad spectrum 
(inhibit a wide range of bacteria, 
yeasts and moulds) (139) 
 
Mutant Lactobacillus salivarius deficient in 
bacteriocin gene are unable to protect mice against 
Listeria monocytogenes infection (138) 
 










Autoinducers are the signalling 
molecules produced and secreted 
by bacteria that form the basis of 
quorum sensing (bacterial 
communication) 
 
Lactobacillus acidophilus La-5 disrupts quorum 
sensing and expression of virulence-related genes 

















Increased intestinal epithelial cell 




Reduced adhesion and invasion of 
intestinal epithelial cells by 
enteroinvasive bacteria resulting in 
reduced translocation 
 
Increased production of human β-
defensin 2 by epithelial cells 
 
 
Stabilisation of intracellular tight 




Epithelial cell regeneration and 
reduced apoptosis 
Lactobacillus plantarum 299v: increased mucin 
gene expression in vitro (142) and adherence to 
colonic cells via a mannose-specific adherence 
mechanism (143) 
 
Lactobacillus casei rhamnosus adheres to colonic 




E. coli Nissle 1917: increase in mucin gene 
expression (145) and production of human β-
defensin 2 by colonic cells (146) 
 
Streptococcus thermophiles and L. acidophilus 
reduce water and chloride secretion in response to 
pathogenic bacteria (147,148) 
 
 
Lactobacillus pretreatment of intestinal epithelium 
reduces disruption of epithelial tight junctions by 
pathogenic E. coli (149). Probiotic preparation 
VSL#3 (see Table 2) prevents redistribution of 
epithelial tight junction proteins on exposure to 
pathogenic bacteria (145). L. rhamnosus GG 
prevents cytokine-mediated apoptosis of intestinal 
epithelial cells (150). L. casei and Clostridium 
butyricum both stimulate gut epithelial 







The probiotic competes with 
pathogen for nutrients and 
adhesion in a microbiological 
niche (130) 
L. casei rhamnosus adheres to colonic cells, 
reduces pathogenic bacterial growth and can 
persist within the gastrointestinal tract  (144,152) 
 
E. coli Nissle 1917 inhibits growth of Shiga-toxin 

















probiotic organisms to influence 
gut-associated lymphoid tissue and 
innate and adaptive host responses 
(154,155). Toll-like receptors play 







Increased promotion of B cells to 





Activation and modulation of 
macrophages, T cells and natural 
killer cells 
 
VSL#3 has been associated with increased anti-
inflammatory and reduced proinflammatory 
cytokine activity, reduced inducible nitric oxide 
synthase and matrix metalloproteinase activity in 
patients with pouchitis (157). L. plantarum 299v 
increases IL-10 secretion from macrophages and T 
cells in patients with ulcerative colitis (158). L. 
casei and L. bulgaricus significantly reduce TNFα 
release from inflamed mucosa in Crohn’s disease 
(159). E. coli Nissle 1917 shows local and 
systemic anti-inflammatory effects in a murine 
model of lipopolysaccharide-induced sepsis (160) 
 
L. rhamnosus GG: increased circulating IgA, IgG 
and IgM concentrations in children with 
gastroenteritis (161,162). Pretreatment with 
probiotic prior to typhoid vaccination leads to 
increased anti-typhoid antibody titres (163) 
 
L. casei Shirota: cell wall structure potently 
induces IL-12 production and the probiotic 
differentially controls the inflammatory cytokine 
responses of macrophages, T cells and natural 
killer cells (164–166). L. casei Shirota and B. 
breve administered preoperatively to biliary cancer 
patients significantly reduce postoperative IL-6, C-
reactive protein and white cell count 
concentrations (164). L. acidophilus and B. 
longum increased macrophage phagocytic activity 


























GesmbH, Vienna, Austria) 
L. casei rhamnosus 109 CFU twice daily via 
nasogastric tube (144) 
 
Ecologic 641 
(Winclove Bio Industries, 
Amsterdam, the Netherlands) 
 
Six different strains of bacteria: L. 
acidophilus, L. casei, L. salivarius, 
L. lactis, B. bifidum, and B. lactis 
(previously classified as B. 
infantis), plus cornstarch and 
maltodextrins 
Administered twice daily via 
nasojejunal tube to a total daily 




(Nutergia, Capdenac, France) 
 
 
Predominantly L. rhamnosus GG, 
but also L. casei, L. acidophilus 
and B. bifidum 
 
One capsule contains 2×1010 
lyophilised bacteria. Capsules can 
be broken and given via enteral 
feeding tube. Five capsules 
administered over 24 hours in 
critically ill patients (169) 
Mutaflor 
(Ardeypharm GmbH, Herdecke, 
Germany) 
 
E. coli Nissle 1917 2.5×109 to 25×109 bacteria per 
capsule. Adult dose 1 or 2 capsules 
per day (170) 
 
Proviva 
(Skanemejerier, Malmo, Sweden) 
 
L. plantarum 299v and oatmeal 
500ml 
 
Oatmeal-based drink containing 
5×107 CFU ml-1. Dose of 500 ml 
day-1 used by McNaught et al (171) 
 
Synbiotic 2000 (Medipharm, 
Kagerod, Sweden 
and Des Moines, IA, USA) 
 
 
A probiotic mixture comprising 
Pediacoccus pentosaceus 5-33:3, 
Leuconostoc mesenteroides 77:1, 
Lactobacillus paracasei ssp., 
paracasei F19, L. plantarum 2362 
plus β-glucan, inulin, pectin and 
resistant starch 
Administered twice daily via 
feeding tube or orally (172) 
 
Synbiotic 2000 Forte 
(Medipharm, 
Kagerod, Sweden 
and Des Moines, IA, USA) 
 
A probiotic mixture comprising P. 
pentosaceus 5–33:3, L. 
mesenteroides 32–77:1, L. 
paracasei ssp. paracasei 19 and L. 
plantarum 2362, plus inulin, oat 
bran, pectin and resistant starch 
 
Sachet for reconstitution 
containing 1010 bacteria plus 10g 
prebiotic fibre. Administered in 
doses of 12 g (1 sachet) per day for 
a 15-day study period (173) 
 
Trevis 
(Christen Hansen, Hørsholm, 
Denmark) 
 
L. acidophilus La5, L. bulgaricus, 
B. lactis 
Bb-12 and Strep. thermophilus 
4×109 CFU/capsule. One capsule 





(Ferring Pharmaceuticals, West 
Drayton, UK) 
 
Four strains of Lactobacillus (L. 
acidophilus, L. casei, 
L. plantarum, L. delbrueckii), three 
strains of Bifidobacterium (B. 
infantis, B. longum, B. breve) and 
one strain of Strep. salivarius 
subsp. Thermophilus 
 
Powder for reconstitution with 
water or to be mixed with cold 
foods prior to consumption. One 
sachet contains 4.5×1011 lactic acid 
bacteria. Also available as a 
capsule containing 2.25×1011 
bacteria. Adult dose 0.5 to 8 
sachets (2 to 32 capsules) per day 
depending upon disease activity. 
Six grams once a day for 12 
months administered by Venturi et 
al (137) 
 





Furthermore, by competing with pathogens for nutrients and adhesion in a microbiological 
niche, probiotics can prevent pathogen replication through a phenomenon known as 
colonisation resistance (130). Probiotics can thus promote the integrity of the gut defence 
barrier and create an unfavourable environment for pathogen colonisation.  
 
Probiotics also exert a range of immunological effects. The interaction between the luminal 
bacteria and the underlying epithelial and mucosal lymphoid cells is referred to as bacterial–
epithelial cross-talk. Crosstalk enables probiotics to have an effect on both the innate and 
adaptive host immune system (154) – for example, promotion of B cells into plasma cells, 
increased production of secretory immunoglobulin A and prevention of activation of the pro-
inflammatory nuclear transcription factor NF-κB (130). Other immunological mechanisms 
include alteration of the cytokine profile and activation of macrophages to present antigen to B 
lymphocytes and increase immunoglobulin production (176). 
 
 
1.5.4 Probiotics in the prevention of non-respiratory infection 
Probiotics have been studied in the prevention of postoperative infection. Three trials in patients 
undergoing major colorectal surgery have shown no significant reduction in postoperative 
infection rates (171,174,175). In each trial, however, the effectiveness may have been limited 
by a relatively short postoperative period of probiotic administration (4 to 5 days).  
 
In contrast, several studies in patients undergoing pancreatic resection (177,178) and hepatic 
resection (164,179) have shown significant reductions in postoperative infection rates of up to 





Liver transplant patients have multiple risk factors for infection, including immunosuppression. 
Two randomised trials have shown probiotics to be safe and effective in this group of patients. 
In the first trial, 95 patients were randomised to receive standard enteral feed plus selective 
bowel decontamination, fibre-containing enteral feed plus live Lactobacillus plantarum 299 
(Lp299) or fibre-containing enteral feed plus heat-killed Lp299 (180). The live Lp299 group 
developed significantly fewer infections than the other two groups (48% vs. 13% vs. 34%, 
respectively). In addition, the mean duration of antibiotic therapy, mean total hospital stay, and 
length of ICU stay were also shorter in the live Lp299 than in the groups with inactivated Lp299 
and selective bowel decontamination. These differences, however, did not reach statistical 
significance. The second trial compared only Synbiotic 2000 and prebiotic fibre, reporting 
postoperative infection rates of 3% and 48%, respectively (172). No serious side effects or 
infections caused by the probiotics were noted in either trial. 
 
Oláh et al randomised 45 patients with severe acute pancreatitis to receive enteral oat fibre and 
live Lp299, or enteral oat fibre and heat-killed Lp299 (181). In the group treated with the live 
probiotic, only one patient required surgery for an infective complication involving the 
pancreas, compared with seven such complications in the control group (P=0.02). There was 
also a non-significant trend towards a shorter length of hospital stay (13.7 days vs. 21.4 days, 
respectively). The same group carried out a single-centre, double-blind, randomised placebo-
controlled trial using Synbiotic 2000 in a further 62 patients with severe acute pancreatitis 
(182). This trial showed no statistically significant differences in the incidence of mortality, 
septic complications or development of multiorgan failure between the two groups. However, 





rate of complications was significantly less in the treatment group versus the control group (8 
vs. 14, P <0.05 and P <0.05, respectively).  
 
The trial that has raised most concern with regard to adverse outcomes and the use of probiotics 
is the PROPATRIA trial (168). In this multicentre, placebo-controlled trial, 296 patients with 
predicted severe acute pancreatitis were randomised to receive the synbiotic preparation 
Ecologic 641 or placebo. This was administered together with fibre-enriched enteral feed via 
the nasojejunal route for 28 days or until discharge. The rate of infective complications was 
similar in both groups (30% vs. 28%) but the mortality rate was higher in the synbiotic group. 
Nine patients in the synbiotic group developed bowel ischaemia, eight of these being small 
bowel ischaemia. There were no cases of bowel ischaemia in the placebo group. One possible 
explanation for this outcome is a difference in the two groups, with more patients in the 
synbiotic group having established organ failure at the time treatment began. An alternative 
theory is that such a significant intestinal burden of bacteria and high-fibre feed could result in 
increased oxygen consumption and local bowel ischaemia. Nevertheless, this is the first time 
such a complication has been reported.  
 
The results of the PROPATRIA trial were surprising as they went against the findings of the 
two previous studies by Oláh et al (181,182), the concern being that the increased mortality 
was a direct result of the treatment, i.e. that the prebiotic-probiotic-fibre mixture led to fatal 
small bowel ischaemia.  
 
The PROPATRIA investigators delivered high doses of enteral feed, fibre and bacteria directly 





received enteral nutrition while receiving vasopressor support for hypotension. This could have 
produced a combination of gut hypoperfusion, reduced absorption of nutrients, fermentation-
related gas production leading to gaseous distension compounding the mucosal ischaemia.  
 
There are a number of other similarities and differences between the three studies worthy of 
mention. All three studies used twice daily nasojejunal administration of the probiotics and all 
three studies used a prebiotic component (i.e. oat fibre, corn starch, pectin) in addition to the 
probiotic formula which already contained fibre. However, the patients in the PROPATRIA 
trial were on average 15 years older than the Oláh studies and there was a higher proportion of 
biliary as opposed to alcohol induced pancreatitis.   
 
The patients in the Dutch trial had higher Imrie scores and CRP levels but lower APACHE II 
scores and less pancreatic necrosis on CT scan compared to the studies by Oláh et al. 
 
Furthermore, the patients in the Dutch trial received a higher number of probiotic species (six 
species of both Lactobacillus and Bifidobacteria at 1010 CFU ml-1) compared to one to four 
Lactobacillus species in the Oláh studies, the duration of treatment was longer (four weeks 
compared to one week) and the Dutch group were more aggressive with enteral nutrition and 
probiotic administration.  
 
These differences raise important questions, for example, regarding the potential effects of the 
type or strain of organism used and their interaction with prebiotics or fibre, and whether the 






1.5.5 Probiotics in the prevention of ventilator associated pneumonia 
Colonisation of the stomach by pathogens or potential pathogens is believed to occur due to a 
combination of poor gut motility, increased gastric pH (due to acid suppression) and the use of 
broad-spectrum antibiotics. This combination of factors leads to an overgrowth of bacteria in 
the duodenum, which reflux into the stomach and are ultimately regurgitated and aspirated into 
the lungs (183).  
 
The normal intestinal microbiota of critically ill patients is altered and replaced by pathogens 
for the reasons alluded to earlier. Therefore, it would seem logical to consider that redressing 
this balance with probiotic organisms may have a role in reducing gastrointestinal colonisation 
by pathogens, and thus, in the prevention of respiratory infection in this population. In addition, 
the restoration of gut barrier function may confer additional immunomodulatory benefits. A 
number of studies have provided evidence that probiotics reduce the incidence of VAP, 
however, none of the studies published to date have looked at E. coli Nissle in this context. 
 
To date, the studies of probiotics in the prevention of VAP have been relatively small and have 
yielded conflicting results in subsequent systematic reviews and meta-analyses (184).  The 
systematic review by Watkinson et al in 2007 examined the use of prebiotics, probiotics and 
synbiotics in 999 adult critical care patients from eight randomised controlled trials. The authors 
concluded that there was no benefit in probiotic prophylaxis for VAP (185).  
 
However, in 2010 Siempos et al examined five randomised controlled trials of 689 patients and 
showed that probiotic administration was associated with a lower incidence of VAP when 





Importantly, both of these were published before the studies by Morrow (104), Oudhuis (187) 
and Barraud (169). 
 
In the literature review conducted prior to commencing the PECaN-ED trial,  eight randomised 
controlled trials of probiotic therapy as a strategy to prevent VAP (104,169,173,187–191) were 
identified. The inclusion criteria, sample size (range 50 to 259), populations studied and 
diagnostic criteria for VAP varied widely between the studies. The probiotic formulae, dosing 
and route of administration also varied but all trials contained Lactobacillus species. (see Table 
1.9).  
 
Six of the eight RCTs demonstrated a lower incidence of VAP in the probiotic group 
(104,173,187,188,190,191), however, this difference was statistically significant in only three 
of the trials (104,173,188). Interestingly, one trial used chlorhexidine oral disinfection as a 
control and found that probiotic Lp299 was at least as effective as the antiseptic in preventing 
oropharyngeal colonisation (61.9% vs. 34.8% new colonisation, respectively; P=0.13) (190). 
The trial by Forestier et al demonstrated no difference in incidence of VAP between groups but 
did demonstrate a median delay in respiratory colonisation with Pseudomonas aeruginosa of 
50 days versus 11 days in controls (P=0.01) (189). This is the most commonly isolated 
antibiotic-resistant Gram-negative species in VAP (192). 
 
The trial by Morrow et al is unique in that it included oropharyngeal slurry as one of the routes 
of administration for the probiotic (104). The group randomised 146 ventilated patients, who 
were considered at high risk for VAP, to receive probiotic L. rhamnosus GG or placebo (inulin) 





was microbiologically confirmed VAP based on quantitative culture of distal airway samples 
obtained by bronchoscopy. The incidence of VAP was significantly reduced in the probiotic 
group (19.1% with probiotic vs. 40.0% with placebo, P=0.007). 
 
The rates of oral colonisation with pathogenic species at 72 hours (70% for placebo vs. 38.2% 
for Lactobacillus, P<0.001) correlated with development of VAP (Pearson correlation 
coefficient=0.22, P=0.009). Interestingly, the probiotic treatment appeared to preferentially 
reduce rates of infection caused by Gram-negative pathogens (22.8% for placebo vs. 8.8% for 
Lactobacillus, P=0.02) while having no statistically significant effect on Gram-positive species 
(12.8% vs. 5.8%, P=0.16) (104). 
 
The question regarding the use of probiotics for the prevention of VAP has generated sufficient 
discussion and debate to form the subject of a Cochrane Review by Bo et al (184) (appendix 
VI). Prior to this, the meta-analysis by Siempos et al (186), mentioned earlier in this section, 
showed that probiotics reduced the incidence of VAP. However, the results of this meta-
analysis were questioned by Van Silvestri et al due to the selection methodology applied (193). 
Following the Siempos meta-analysis, three further RCTs looking at probiotics in the 
prevention of VAP, were published by Baraud, Morrow and Tan et al (104,169,194), which all 
showed that probiotics were safe and effective in preventing VAP.  
 
The Cochrane Review included RCTs and excluded quasi-RCTs, controlled clinical trials, 
controlled before and after studies, interrupted time series studies, cross-over studies and 
cluster-RCTs. It was restricted to adult ICU patients 18 years of age or older who were 





all-cause mortality (including ICU mortality, 28/30-day mortality, hospital mortality or 
mortality at an unspecified time) and safety (including incidence of diarrhoea). Secondary 
outcomes included length of ICU stay and duration of mechanical ventilation. 
 
Eight RCTs were identified which met criteria for inclusion in the analysis and compared a 
probiotic treatment group to a control. The sample size in these studies ranged from 50 to 264 
(total 1083 patients), all of which reported VAP incidence as an outcome (104,169,173,188–
191,194). The Cochrane analysis of VAP incidence included 1018 patients. This showed that 
the use of probiotics decreased the incidence of VAP (OR 0.70, CI 0.52-0.95), however, the 
evidence on which it was based was graded as low quality.  
 
In terms of ICU mortality, the combined results were uncertain, with OR 0.84 (CI 0.58 to 1.22). 
This was based on evidence graded as very low quality (184). Similarly, the analysis of hospital 
mortality (OR 0.78, CI 0.54-1.14), length of ICU stay (mean difference -1.60, CI -6.53-3.33) 
and duration of mechanical ventilation (mean difference -6.15, CI -18.77-6.47) were all based 
on very low quality evidence (184). 
 
The evidence from the available studies analysed in the Cochrane review suggests that use of 
probiotics is associated with a reduction in the incidence of VAP. However, the quality of the 
evidence is low.  The trial by Spindler-Vesel et al did not provide a robust definition of VAP 
(188) which adds a degree of uncertainty to this previous finding. Had this trial been excluded 
from the primary outcome of VAP incidence, the result would no longer be statistically 





to give a definitive answer regarding effect of probiotics on length of ICU stay or hospital 
mortality.  
 
The principal findings of the Cochrane Review were in keeping with the previous meta-analyses 
by Siempos et al (186) and Petrof et al (195), but contradicted the results of the meta-analysis 
by Gu et al (196). The meta-analysis by Siempos et al included five studies with a total of 689 
patients and showed that probiotics appeared to be associated with a lower incidence of VAP. 
The meta-analysis by Petrof et al included 23 studies with a total of 2153 patients and again 
demonstrated a lower VAP incidence in the probiotic group. However, the meta-analysis by Gu 
et al comprising seven studies and a total of 1142 patients showed no evidence of a reduction 
in VAP.  
 
There are several notable differences between these publications. Gu et al excluded two studies 
that were included in the Cochrane Review (Spindler-Vesel et al; Tan et al (188,194)), and 
included one trial that was excluded from (Oudhuis et al (197)). In the trial by Oudhuis et al 
the control group received SDD using an antibiotic regime comprising oral paste and enteral 
solution (polymyxin E, gentamicin, amphotericin B) and intravenous cefotaxime.  
 
The earlier review by Siempos et al did not include data from the studies by Barraud et al, 
Morrow et al or Tan et al (104,169,194). The subsequent review by Petrof et al did not include 
data from the trial by Spindler-Vesel et al (188). 
 
Studies of probiotics in the critically ill have trialled a number of different species, with 





superior in the prevention of infection associated with critical illness. Similarly, the optimum 
administration route, dosage and duration of treatment are not clear. Further research is 
undoubtedly warranted, perhaps considering Gram-negative probiotic species. 
 
1.5.6 Escherichia coli Nissle as a potential candidate in the prevention of ventilator 
associated pneumonia 
Gram-negative bacteria are the causative organisms in the majority of cases of ventilator-
associated pneumonia, particularly Enterobacteriaceae and Pseudomonas aeruginosa (198). 
They are also the potential pathogens colonising the stomach of ventilated patients, and 
therefore, probiotic species of Enterobacteriaceae would appear worthy of consideration and 
further investigation (22,183). 
 
The most extensively studied and widely available probiotic from this family is Escherichia 
coli strain Nissle 1917 (serotype 06:K5:H1). It is a single, flagellated E. coli strain comprising 
5324 genes and two cryptic plasmids. Escherichia coli Nissle produces the bacteriocins 
Microcin M and H47 (199).  
 
The organism was first isolated during the First World War from a soldier who did not develop 
enterocolitis during a shigellosis outbreak (200). Escherichia coli Nissle 1917 has already been 
used in a number of studies looking at ulcerative colitis. These studies demonstrated that the 
probiotic bacteria were as effective as mesalazine in the maintenance of remission (170). 
 
The Nissle bacterium has an excellent safety record with no reports of systemic infection in 





sensitivity (bactericidal effects of normal human serum), together with the complete absence of 
any genes encoding exotoxins, pathogenicity islands and other virulence factors (201).  
 
The Nissle strain does not acquire any pathogenic bacterial DNA and expresses two broad host 
range microcins which interfere with colonisation of mucosal surfaces by other bacteria as well 
as producing factors that prevent adherence and invasion of the intestinal wall by pathogenic 
E. coli and most probably other Gram-negative Enterobacteriaceae (201).  
 
The study by Leatham et al demonstrated that pre-colonisation of the mouse gastrointestinal 
tract with human commensal E. coli encouraged elimination of pathogenic bacteria (E. coli 
O157:H7) (202). In this study, commensal E. coli were first introduced to the mice followed by 
pathogenic E. coli EDL933 (O157:H7) on day 10. Five different human commensals were 
tested, and of these E. coli Nissle 1917 and E. coli EFC1 limited the growth of the pathogenic 
strain (202). 
 
In addition to its strong pathogen displacing properties, E. coli Nissle has been shown to exhibit 
a favourable effect on the inflammatory response in a number of animal models. In a murine 
model of severe sepsis, it was demonstrated that prior administration of E. coli Nissle resulted 
in significantly reduced TNF-α production 24 hours after induction of septic shock (160).  The 
E. coli Nissle treated mice also showed decreased IL-2, IL-5 and IgG expression and increased 
IL-10 expression compared to controls. Myeloperoxidase activity (as an indirect measure of 
neutrophil invasion) was significantly higher in the lungs and colon of the control as compared 
to probiotic treated mice.  Serum IgG was raised in the control group following induction of 





sepsis model is particularly interesting as it suggests that E. coli Nissle may have a role in 
immunomodulation. It could even be suggested that E. coli Nissle potentially has a role to play 
as a novel therapy in Gram-negative sepsis as it promotes the host immune response towards 
anti-inflammatory pathways.  
 
Although the interest in E. coli Nissle, to date, has focused largely on gastrointestinal pathology, 
other potential roles are being investigated in the prevention of device-associated bacterial 
infections. For example, Chen et al have demonstrated that E. coli Nissle biofilms on silicone 
substrates reduced colonisation by pathogenic enterococci (203). 
 
However, as I am focusing on the activity of E. coli Nissle in the stomach, one limitation of this 
trial is the lack of information or a functional assay examining its behaviour and replication in 
a low pH environment. 
 
1.5.6 Administration of probiotics and monitoring of their effects 
Probiotics are commercially available in various preparations including yoghurt-based 
products, capsules, powders and suspensions. The studies in critically ill patients discussed 
above involve enteral administration of a variety of probiotic strains using different dosing 
regimens. In eight of the nine studies involving mechanically ventilated patients (table 1.9), 
probiotic powder or capsule contents were dissolved in water and delivered via a feeding tube 
into the stomach. Morrow et al used an oropharyngeal slurry of L. rhamnosus GG (suspended 
in a sterile water-based surgical lubricant) in addition to nasogastric administration (104). After 
72 hours, the patients receiving this regime were found to have lower rates of oral (38.2% vs. 





than those receiving placebo. Klarin et al used topical application of Lp299 to the oral cavity 
alone and found it to be at least as effective as chlorhexidine 0.1% in reducing oropharyngeal 
pathogenic load (190). 
 
Testing for colonisation of the gastrointestinal tract with the probiotic species is reported in 
only a minority of studies. McNaught et al collected gastric aspirates at induction of anaesthesia 
in elective surgical patients who had received at least one week of oral Lp299 (171). The 
probiotic species was not isolated in any subject. In the trial by Forestier et al, however, gastric 
aspirates were taken at inclusion, at day 7 and at discharge. Lactobacillus casei rhamnosus was 
detected in 52 out of 102 patients on probiotic treatment after a median of 13 days (189).  
 
In the trial by Klarin et al described above, the probiotic species Lp299 was detected in all 
oropharyngeal cultures and in the tracheal cultures from 56% of patients in the probiotic arm 
(190). Knight et al demonstrated detection of probiotic species in stool culture after 3 days 
treatment with Synbiotic 2000 Forte, indicating its survival from the stomach to the distal gut 
(204). However, they did not routinely analyse stool samples in their more recent trial (191). 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.5.7 Quality and safety of probiotics 
Probiotics are now widely available and are being consumed daily in large quantities. Overall, 
they appear to have an excellent safety record, but there are some concerns that are likely to 
lead to caution in their widespread use in clinical practice. 
 
The availability of different probiotics varies from country to country and there can be lack of 
consistency between manufacturers, and even batches, in terms of density of bacteria, adhesion 
characteristics, stability and viability (205). Strain-specific adhesion properties and viability 
have been shown to vary between batches from the same manufacturer, which could lead to 
conflicting clinical trial results (206). 
 
There have been a number of publications reporting serious infections caused by Lactobacillus 
species related to those used as probiotics (207). The Finnish group of Salminen et al examined 
89 cases of Lactobacillus bacteraemia. In 11 cases, the strain was identical with the probiotic 
L. rhamnosus GG, but they could not directly relate these cases to probiotic consumption (208). 
Salminen et al also examined trends in Lactobacillus bacteraemia in Finland over the period 
1990 to 2000. This period coincided with a rapid increase in the consumption of probiotic L. 
rhamnosus GG. However, the group concluded that increased probiotic use had not led to an 
increase in Lactobacillus bacteraemia (209). 
 
There are some case reports in the literature of Lactobacillus infection and bacteraemia that do 
appear to be directly related to probiotic consumption (210–213). All of the patients involved 
were immunocompromised to some degree and the causative organism was linked to the 





Infections caused by Lactobacillus species from probiotics have also been reported in 
immunosuppressed patients – including those with acquired immunodeficiency syndrome 
(AIDS) and those following lung and liver transplantation (214–216). Lactobacillus 
bacteraemia has been associated with structural heart abnormalities, valve prosthesis or prior 
endocarditis (217). However, the majority of clinical trials using Lactobacillus species 
probiotics have reported few adverse effects. 
 
The only reported infection associated with E. coli Nissle 1917 is in a premature neonate 
(gestational age 28 weeks) (218). The child had an extremely low birth weight of 935g and 
developed gastroenteritis due to rotavirus and adenovirus 14 days into the postnatal period. E. 
coli Nissle treatment initially led to improvement but the child developed severe sepsis 10 days 
later and subsequently E. coli Nissle 1917 was isolated in blood cultures. The child was treated 
with antibiotics and made a full recovery. 
 
An additional aspect to the trial by Morrow et al was the data collected on the incidence of 
Clostridium difficile and ICU-associated diarrhoea (diarrhoea not caused by C. difficile) (104). 
The probiotic group had significantly less C. difficile cytotoxin-positive diarrhoea compared to 
the placebo group (5.6% vs. 18.6%, P=0.02), although the duration of C. difficile cytotoxin-
positive diarrhoea in those patients receiving probiotics was not significantly less than those 
with C. difficile cytotoxin-positive diarrhoea in the placebo group . However, patients treated 
with probiotic did receive fewer days of antibiotics for C. difficile-associated diarrhoea (0.5±2.3 
days vs. 2.1±4.8 days in placebo group, P=0.02). The duration of ICU-associated diarrhoea was 






Adverse events were examined as a secondary outcome in the Cochrane review by Bo et al 
(184). The three trials which reported on the incidence of diarrhoea (which was initially 
included as an adverse outcome) were examined and the pooled results indicated no clear 
evidence of a difference (OR 0.72, CI 0.47-1.09) (184). Six studies ,with a total of 430 probiotic 
treated patients, reported no adverse events in the form of nosocomial probiotic infections 
(104,169,173,189,191,194). However, the authors concluded that the results of this meta-
analysis did not provide sufficient evidence to draw firm conclusions on the efficacy and safety 
of probiotics for the prevention of VAP in ICU patients. 
 
A wide range of probiotic species is being investigated for an increasing number of indications. 
There has been little work carried out on the rationale behind which probiotics are used and in 
what combination. Timmerman et al attempted to address this issue by examining specific 
strains in an attempt to produce an effective multi-species mixture (219). The synbiotic 
preparation Ecologic 641 was used in the PROPATRIA trial. This group selected six strains of 
Lactobacillus based on survival in a simulated gastrointestinal environment, antimicrobial 
activity and ability to induce IL-10, highlighting the point that there should be a disease-specific 
rationale for selection of probiotics. 
 
We are still far from fully understanding the probiotic–host interaction, however, given the 
potential benefits that probiotic bacteria have to offer and the association with reduction in VAP, 
further study is clearly warranted. Careful consideration should be given to further well-








It was hypothesised that twice daily nasogastric administration of 5 ml or 15 ml of E. coli Nissle 
1917 suspension to invasively ventilated ICU patients would lead to successful gastric 
colonisation, and significantly reduce ICU acquired gastric colonisation by pathogenic or 
potentially pathogenic Gram-negative bacteria compared to a non-treatment control.  
 
1.7 Aims of the Thesis  
This thesis is a report of the proof of concept, open-label, randomised, non-treatment control 
feasibility study PECaN-ED (Probiotic E. coli Nissle – Efficacy and Dosing).  
 
The specific aims of this study were: 
1. To determine whether gastric colonisation with E. coli Nissle could be demonstrated in 
invasively ventilated ICU patients. 
2. Investigate whether a higher dose of E. coli Nissle would allow gastric colonisation to 
occur within a shorter time period or in a higher proportion of patients. 
3. Determine whether gastric colonisation by pathogenic or potentially pathogenic Gram-
negative bacteria could be reduced by administration of E. coli Nissle. 
4. Evaluate the safety and tolerability of E. coli Nissle administered via the nasogastric 





















2.1 Ethical and MHRA approval 
The trial was conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki.  Approval from a Research Ethics Committee (REC) (reference 
11/SC/0423) and Clinical Trial Authorisation from the Medicines and Healthcare products 
Regulatory Agency (MHRA) (reference 24698/0010/001-0001), were obtained before starting 
the study.  
 
Research and Development approval was also obtained from the Heart of England NHS 
Foundation Trust (HEFT) (reference 2011074AN) which acted as sole sponsor for this study. 
The study was registered with the European Clinical Trials Database, EudraCT reference 
number 2011-002343-99. 
 
Details of the trial were submitted to EudraCT, The European Clinical Trials Register. The 
information submitted provided a summary of the clinical trial and contact details if further 
information was required. As this was a feasibility study for an MD thesis, no protocol 
publication was undertaken. The registration of the trial on the European Clinical Trials 
Register fulfilled the ethics requirement for details of the trial to be available on an accessible 
database. The Eudract registration is available at the following URL: 
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002343-99/GB. 
 
The patients who participated in this study were, by definition, unable to provide informed 
consent as they were sedated and ventilated.  Therefore, consent was sought from the patients’ 
legal representatives. Ethical approval was obtained for this process, and for the use of either a 





was defined as a person who is close to the patient, willing and capable to act in this role for 
the purpose of this study. The ProLR was defined as the doctor primarily responsible for the 
medical treatment provided to the patient and not connected with the conduct of this study. In 
both instances the representative was provided with an information sheet explaining the study. 
The representative was given adequate time to read the document, discuss with relatives or 
colleagues and ask questions about the research itself or conduct of the study. The 
representative provided consent for the patient to take part in the study, believing that the patient 
would not have objected to being part of this research.   
 
It is acknowledged that a representative is providing consent on behalf of a patient for the 
purposes of a CTIMP and that this is performed in accordance with current International 
Conference on Harmonization (ICH) guidelines on Good Clinical Practice (GCP). This 
technique has been used successfully in other clinical trials (e.g. PAC-Man, TracMan and Balti-
2 trials) undertaken in the ICU setting. 
 
Retrospective consent was sought if and when the patient was able to provide fully informed 
consent (usually following ICU discharge) The patient was provided with an information sheet 
and asked to provide their consent to be included in the study. If the representative withdrew 
consent or the patient declined, no further study treatment would be administered, and the 









2.2 Trial management 
As agreed with the study sponsor, the trial was overseen by the Trial Management Group 
(TMG). This comprised the Chief Investigator, Principal Investigator, Professor of 
Microbiology, Senior Research Nurse, and other members of the Academic Department of 
Critical Care.  As a single centre, feasibility study it was decided that there was no requirement 
for a separate Data Safety and Monitoring Committee. The TMG met monthly and reviewed 
patient data for safety throughout the trial. The TMG had access to the full data set and were 
not blinded to any data or information. 
 
2.3 Study protocol 
This proof of concept study was designed to establish the efficacy and dosing range of E. coli 
Nissle by addressing the aims outlined in section 1.7, and to establish feasibility in this patient 


































Screening for eligibility: 
1.Invasive ventilation <24hours 





   
Randomisation within 24 hours of intubation by sealed 
envelope (1:1:1) 
n=10 




E. coli Nissle 15 ml b.d. (15ml ECN) 
 
Day 0: 
IMP dosing at 10:00 & 22:00. Baseline samples collected before first 
dose of IMP. If >6 hours until first timed dose, stat dose given. 
Day 1: 
• Gastric aspirate & Oropharyngeal aspirates/swabs 
• Tracheal aspirate, Urine sample & Stool sample/Rectal swab Suspected VAP 
• Suspected VAP - BAL if clinically necessary 
Day 2: 
• Gastric aspirate & Oropharyngeal aspirates/swabs 
• Tracheal aspirate, Urine sample & Stool sample/Rectal swab Suspected VAP 
• Suspected VAP - BAL if clinically necessary 
Day 3: 
• Gastric aspirate & Oropharyngeal aspirates/swabs 
• Tracheal aspirate, Urine sample & Stool sample/Rectal swab Suspected VAP 
• Suspected VAP - BAL if clinically necessary 
Day 4: 
• Gastric aspirate & Oropharyngeal aspirates/swabs 
• Tracheal aspirate, Urine sample & Stool sample/Rectal swab Suspected VAP 












Figure 2.1 Consort flow diagram showing PECaN-ED Study Protocol 
 
 
The following primary and secondary endpoints were used to establish if the hypothesis was 
true: - 
The primary endpoint was the detection of successful gastric colonisation with E. coli Nissle 
following nasogastric administration in ventilated ICU patients. The primary end point was 
defined as the presence of E. coli Nissle in two consecutive gastric aspirates, although the 
treatment was continued for entire duration of ventilation. The presence of E. coli Nissle strain 
was confirmed by PCR analysis against a standard. 
 
The secondary endpoints examined in the study were: 
• The effect of dose variation on the frequency of gastric colonisation by E. coli Nissle 
• The effect of dose variation on the time to gastric colonisation by E. coli Nissle 
• The proportion of gastric aspirates colonised by potentially pathogenic Gram-negative 
bacteria after 48 hours ICU stay compared to baseline 
Day 5 Onwards: 
• Daily gastric aspirates & Oropharyngeal aspirates/swabs 
• Tracheal aspirate, Urine sample & Stool sample/Rectal swab alternate days 
• Suspected VAP – BAL if deemed clinically necessary 





• The proportion of oropharyngeal aspirates colonised by potentially pathogenic Gram-
negative bacteria after 48 hours ICU stay compared to baseline 
• The proportion of tracheal aspirates colonised by potentially pathogenic Gram-negative 
bacteria after 48 hours ICU stay compared to baseline 
• The incidence of ventilator-associated pneumonia in the study population 
• An analysis of antibiotic days for the study population 
• The cumulative incidence of ICU-acquired infection; defined as positive 
microbiological results from all types of samples 
• The ICU, hospital and 28-day mortality for the study population 
 
 
2.4 Patient recruitment  
The study took place in the Intensive Care Unit (ICU) at Birmingham Heartlands Hospital. This 
is a university affiliated teaching trust with a total of 1449 in-patient beds spread over three 
sites that receives patients from the north and east of Birmingham. Heartlands Hospital is 
situated in east Birmingham and has a 19-bed general ICU. 
 
The Intensive Care National Audit and Research Centre (ICNARC) HEFT database showed 
that there were 1214 adult ICU admissions at Birmingham Heartlands Hospital in 2012. The 
number of patients receiving invasive ventilation was 465 and, of these, 248 patients (53%) 
were ventilated for 48 hours or more. 
 
Based on the trial by Forestier et al (189), who demonstrated a 30% recruitment rate from the 





We anticipated recruiting approximately 3 patients per month, allowing recruitment of 30 
patients within 10-12 months, which translated to 10 patients per arm. This was deemed to be 
achievable within the timelines of the study and large enough to see an effect of the IMP, to 
dose the IMP and to determine if it was feasible to undertake a larger trial of this nature. 
 
Potential study participants were screened for eligibility based on the following inclusion and 
exclusion criteria.  These were based on criteria from similar probiotic studies and also on the 
consensus of clinical opinion as to which patients may be in higher risk groups for developing 
a VAP. This was based on clinical prediction of duration of invasive ventilation as opposed to 
a screening marker of risk, such as lymphopaenia.  
 
Although E. coli Nissle has an excellent safety record, this was the first time that it had been 
administered to critically ill patients; hence a high degree of caution was used. 
 
Inclusion criteria: 
• age ≥ 18 years, and  
• Invasive ventilation for ≤24 hours, and  
• expected duration of mechanical ventilation of ≥48 hours.  
 
Exclusion criteria: 
• imminent treatment withdrawal 
• pregnancy or lactation  
• immunosuppressant therapy 





• gastrointestinal bleeding 
• prosthetic cardiac valve or vascular graft 
• cardiac trauma 
• history of rheumatic fever, endocarditis or congenital heart disease 
• contraindication to enteral feeding 
• gastro-oesophageal or intestinal injury or foregut surgery during the current admission 
• acute pancreatitis  
• participation in an interventional clinical trial within the last 30 days 
 
Intensive care patients, who had been intubated by the oro-tracheal route, were reviewed to 
determine if they fulfilled the eligibility criteria for the study. A screening log was kept of all 
patients who were reviewed for the study, this detailed if they were eligible for inclusion or not, 
and reasons for non-recruitment. The most common reason for non-recruitment was uncertainty 
about duration of mechanical ventilation. It is recognised that the accuracy of early clinical 
prediction of duration of mechanical ventilation is limited (220). This is an important factor to 
take into consideration and has an important bearing on a study such as this. 
 
2.5 Randomisation 
Patients were randomised to one of three study groups: 
1. to receive E. coli Nissle suspension 5ml bis in die (b.d.) 
2. to receive E. coli Nissle suspension 15ml b.d. 






Randomisation was in a 1:1:1 ratio using the sealed envelope technique. The sealed envelopes 
were prepared by a Critical Care Research Administrator, who was independent of the study, 
and kept securely in the Critical Care Research Department. Only one envelope was released 
after each informed consent was received. Those patients randomised to a treatment group 
received the first dose of probiotic suspension within 12 hours of randomisation. 
 
2.6 The Investigational Medicinal Product  
Full details of the Investigational Medicinal Product (IMP) are given in the Summary of Product 
Characteristics in Appendix V.  
 
Active ingredient: Escherichia coli Nissle 1917 suspension  
Concentration: 108 viable cells per ml 
Container:  5ml polyethylene ampoules  
Manufacturer:  Pharma-Zentrale (Ardeypharm) GmbH, Germany  
Supplier: Sharp Clinical Services (UK) Limited (formerly Bilcare GCS (Europe)) 
 
The IMP was received by the Clinical Trials Pharmacy at the Heart of England NHS Foundation 
Trust, directly from the importers Sharp Clinical Services (UK) Limited. The IMP was imported 
from Pharma-Zentrale GmbH, Germany, in boxes of 32 x 5ml ampoules. These boxes were 
packed down, assembled and labelled as agreed by the Clinical Trials Pharmacy in accordance 
with annex 13 of EU legislation and under regulation 37 of the Medicines for Human Use 
(Clinical Trials) regulations. The IMP was stored between 2-8°C and this was monitored by the 
Clinical Trials Pharmacy at HEFT in compliance with the Medicines and For Human Use 





Following randomisation, a clinical trial prescription was prepared, according to the 
randomisation arm; this was then taken to the Clinical Trials Pharmacy at HEFT for the relevant 
IMP pack to be dispensed. As patients were recruited and randomised into the study outside 
normal pharmacy hours, drug packs were available on ICU at all times. These were temperature 
monitored in accordance with the relevant regulations.   
 
2.7 Probiotic administration 
Patients who were randomised to probiotic therapy received 5 x 108 (1 x 5ml ampoule) or 15 x 
108 (3 x 15ml ampoules) viable cells per ml of E. coli Nissle on a twice daily basis. The E. coli 
Nissle suspension was administered via standard 8 French 105 cm polyurethane nasogastric 
feeding tube (Merck Corflo™) at 10:00 and 22:00. After administration, the nasogastric tube 
was flushed with 10ml sterile water and feeding recommenced. Gastric aspirate samples were 
obtained prior to the 10:00 dose of probiotic (see section 2.10). The third group, non-treatment 
control group, received routine clinical care. 
 
Patients remained in the trial, with treatment groups receiving the IMP, until reaching the stage 
of unassisted breathing or death. This is in keeping with similar studies of probiotics. As per 
the trial protocol, unassisted breathing was defined as one of the following: - 
1. Extubation to face mask, nasal prong oxygen, or room air 
2. T-tube breathing 
3. Tracheostomy mask breathing 







As this was the first time that the IMP had been used for this purpose and in this group of 
patients, one of the questions that I set out to examine was that of dosing. Therefore, two 
different dosing regimens were selected, which it was felt would deliver an adequate quantity 
of viable cells to allow demonstration of gastric colonisation. This decision, and the doses used, 
were based on a combination of expert microbiological opinion, information obtained from the 
manufacturer, Ardeypharm GmbH, and comparison with the dosing regimens used in previous 
probiotic studies. For example, Morrow et al used a dose of 2x109 CFU b.d. In this study 5x108 
and 15x108 CFU b.d. were selected. 
 
All patients received enteral nutrition via the nasogastric tube according to local protocols and 
was not affected by probiotic administration. PPIs or H2RAs were also administered routinely 
according to the local ventilator care bundle. 
 
The research team and clinical staff were aware of the treatment that the patient was randomised 
to receive; hence the trial was open label. As this was a feasibility and dosing study, an open 
label design was used to help the research team identify any difficulties with administration. In 
addition, it was felt to be important for staff administering the IMP to be cognisant that they 
were handling a concentrated solution of bacteria, in order to avoid cross contamination. As 
this was a feasibility study, an open label design was acceptable. The control group for this 
study did not receive any treatment in relation to the trial, purely sample collection. The 







The study was open label in terms of the clinical interventions and drug administration for the 
reasons described above. This raises the obvious point about the inherent bias of an open-label 
study. However, we sought to mitigate against this by blinding the outcome assessment. Only 
two microbiologists carried out all of the laboratory work. Neither had access to or knowledge 
of the patient identity or the study group allocation until all sample analysis had been completed 
for each patient. 
 
2.8 Data collection 
Data collected from the study patients included demographic details, primary ICU diagnosis, 
co-morbidities, antibiotic history for the current admission, observations on admission, baseline 
haematology and biochemistry results. These are shown in table 2.1. 
 
Data was also collected daily for the duration of the study which included physiological, 
haematological and biochemical data. Details of antibiotic therapy, routine clinical 
microbiology and organ support requirements were also collected. In addition, the following 
outcome data were collected – length of ICU and hospital stay and ICU, hospital and 28-day 
mortality. 
 
2.9 Severity of illness scores 
Data collected from the study, together with information from the Intensive Care National Audit 
and Research Centre (ICNARC) database were used to calculate severity of illness scores for 
the enrolled patients. These scoring systems were used to ensure that the patients across the 
three groups were well-matched in terms of severity of illness. Scores were recorded at the time 


















Blood pressure & Mean arterial pressure (mmHg) 
Respiratory rate (Breaths per minute) 
Partial pressure arterial Oxygen/Carbon Dioxide (PaO2/CO2) 
Fractional inspired Oxygen (FiO2) 
Glasgow Coma Scale (GCS) 
Urine output (ml hour-1) 
Vasoactive drugs 
Baseline Investigations 
White cell count (x109 l-1) 
Haematocrit (%) 
Urea & creatinine (µmol l-1) 
Sodium (mmol l-1) 
Potassium (mmol l-1) 
pH/Bicarbonate (mmol l-1) 
Bilirubin (µmol l-1) 
Albumin (g l-1) 
Glucose (mmol l-1) 
 
 








2.9.1 APACHE II Score 
The acute physiology and chronic health evaluation (APACHE) score is a severity of illness 
scoring system which is applied to patients within 24 hours of admission to ICU (table 2.2). 
The original score was described in 1981 and has undergone several revisions since then. The 
APACHE II score was described in 1985 and is the most frequently used intensive care seventy 
of illness scoring system. It incorporates 12 routinely measured parameters, and these are 
weighted for degree of derangement with a score from 0-4. Age, chronic health conditions and 
surgery are also taken into account. A score from 0-71 is generated and this is integrated with 
the patient’s diagnosis to calculate an estimate of hospital mortality. Higher scores correspond 
to increased severity of illness and a higher probability of death (221). 
 
2.9.2 APACHE III Score 
This is the latest version of the APACHE scoring system, introduced in 1991, which attempts 
to improve the risk prediction of the APACHE II system (table 2.2). APACHE III stands for 
acute physiology, age and chronic health evaluation. It consists of a numerical score from 0-
299 obtained from the scores assigned to the physiological measurements, chronological age 
(with the emphasis reflected by the change in the second ‘A’) and chronic health status. 
APACHE III uses data from 16 physiological measurements as well as a modified chronic 
health component. APACHE III also uses 78 disease definitions to group patients according to 
the principal reason for ICU admission (222).  
 
2.9.3 SAPS II Score  
The simplified acute physiology score (SAPS) II is a severity of illness scoring system which 





similar way to the APACHE scoring systems. A score from 0-163 is generated and probability 
of death is calculated using logistic regression. SAPS II is superior to APACHE II for the 
comparison of disease severity  in patients with different pathologies (223).  
 
2.10 Sample collection 
A full schedule of assessments and samples collected for the study patients is shown in table 
2.3. 
 
A routine set of ICU blood tests was taken on a daily basis from ventilated patients using the 
indwelling arterial or central venous cannula. From these blood tests it was possible to obtain 
the required haematological and biochemical results. 
 
Gastric aspirates were obtained from patients immediately prior to administration of the 10:00 
dose of E. coli Nissle suspension and were collected daily for the duration of the study. The 
gastric aspirate sample was obtained by attaching a sterile 20 ml Enteral-IsoSaf™ syringe to 














APACHE II APACHE III SAPS II 
Temperature Temperature Temperature 
Heart rate Heart rate Heart rate 





A-a D O2 
PaO2/FiO2 ratio 




Serum sodium Serum sodium Serum sodium 
Serum potassium Serum albumin Serum potassium 
Arterial pH/Serum Bicarbonate pH/pCO2 Serum Bicarbonate 
White cell count White cell count White cell count 
Glasgow Coma Scale Neurological score Glasgow Coma Scale 
Haematocrit  Haematocrit Admission type 
Age Age Age 
Chronic health Chronic health Chronic health 
- Serum Glucose - 
- Serum Bilirubin - 
- Origin/Reason for ICU admission - 
 
PaO2/FiO2 - partial pressure of oxygen/fractional inspired oxygen. A-a D O2 - Alveolar- arterial oxygen difference. 
pCO2 - partial pressure of carbon dioxide 
 
Table 2.2 Components of the Acute Physiology and Chronic Health Evaluation score 
(APACHE II), Acute Physiology, Age and Chronic Health Evaluation (APACHE III) and 








































the left and a further attempt was made after 20 minutes. If insufficient aspirate was obtained 
after turning, 20 ml of sterile water was instilled and aspirated. Up to 10 ml of gastric aspirate 
was then placed in a sterile 30ml Sterilin™ polystyrene universal container (ThermoFisher 
Scientific, USA) and transported to the laboratory for processing and analysis. 
 
In retrospect this is a limitation of the study methodology. Data on nasogastric aspirates which 
were difficult to obtain or required diluted gastric sampling were not recorded. This would have 
had a more significant bearing if fully quantitative analysis of the samples was carried out. 
However, it is an important point to consider for future work. 
 
Oropharyngeal swabs or aspirates were obtained from patients on a daily basis, prior to 
administration of the 10:00 dose of E. coli Nissle suspension and prior to routine mouth care, 
for the duration of the study. A sterile Yankauer suction device (LY-3600, Pennine Healthcare) 
or sterile 14 French suction catheter (Ref 2141 Covidien™ Argyle™ Gentle Flow suction 
catheter) was attached to a sterile sputum trap (Trachea Suction Set ref 24006182, Unomedical, 
ConvaTec limited) and a sample obtained from the oropharynx. If the sample of oropharyngeal 
secretions was inadequate, a bacterial swab (eSwab™ Copan Italia SpA) was used to obtain a 
sample from the oropharynx.  
 
Dry tracheal aspirates were obtained in a standard fashion using a 14 French closed 
endotracheal suction circuit (reference 227-5 Turbo-Cleaning Closed Suction System for 
adults, Halyard, Belgium) prior to administration of the 10:00 dose of E. coli Nissle suspension 
and prior to routine mouth care. The tracheal aspirate sample was collected in a sterile sputum 





collected on enrolment, on the three subsequent days and thereafter on alternate days for the 
duration of the study. 
 
A catheter specimen of urine (CSU) was collected in a sterile 30ml Sterilin™ polystyrene 
universal container (ThermoFisher Scientific, USA) using a standard technique. Samples were 
collected on enrolment, on the three subsequent days and thereafter on alternate days for the 
duration of the study. 
 
A stool sample (formed or unformed) was collected in a sterile 30ml Sterilin™ polystyrene 
universal container with spoon (ThermoFisher Scientific, USA) on enrolment, on the three 
subsequent days and thereafter on alternate days for the duration of the study. If a stool sample 





Figure 2.2 Procedure for obtaining a rectal swab (Adapted from Shropshire County and 






1) Obtain a rectal swab by carefully inserting a swab 2.5 cm (1 inch) beyond the anal 
sphincter (eSwab™ Copan Italia SpA) 
2) The swab should be rotated gently & withdrawn; if no faecal staining is seen, gently re-
introduce a little further 
3) Patients who have had a low colorectal anastomosis should not have a rectal swab taken 
unless a surgical consultant has given permission 
 
 
If VAP was suspected, then bronchoscopic BAL with quantitative culture was performed if 
deemed clinically appropriate. This was based on the modified criteria described by Singh et al 
(40). A score of >6 based on the first five CPIS criteria (fever, leucocytosis, quality of 
secretions, oxygenation and radiographic changes) was considered to be suggestive of VAP. 
 
A standardised BAL technique was used, based on that described by Morris et al (224). The 
bronchoscope was wedged in a subsegment corresponding to the area of focal radiological 
involvement. In cases where the radiographic change was more diffuse, the bronchoscope was 
wedged in a subsegment producing visible purulent secretions or, in the absence of purulent 
secretions, in the posterior segment of the right lower lobe. A 20 ml aliquot of sterile saline was 
instilled and the aspirate (bronchiolar sample) discarded, then further 20 ml aliquots of sterile 
saline were instilled and the aspirate (alveolar sample) collected for microbiological analysis in 
a sterile sputum trap (Trachea Suction Set ref 24006182, Unomedical, ConvaTec limited).  
 
On completion of the study, the HEFT microbiology results system was interrogated for any 
relevant positive results from routine clinical sampling, including tracheal aspirates, urine 





which arose from this search were correlated with clinical data to determine if there was any 
infection or evidence of colonisation relevant to the study. 
 
2.11 Sample processing 
All microbiology samples were processed (including the MALDI-TOF and PCR analysis) in 
the Public Health England (PHE) Laboratory at Birmingham Heartlands Hospital. This 
laboratory is registered with the United Kingdom Accreditation Service (UKAS), details of 
which can be found at the following URL: https://www.ukas.com/wp-
content/uploads/schedule_uploads/00007/8213%20Medical%20Single.pdf.   
 
Samples were processed during working hours, Monday to Friday. If samples were collected 
outside these hours, they were stored in the designated microbiology refrigerator until the next 
working day.  
 
All samples were inoculated onto the following plates - blood agar, CPS ID2 (BioMérieux Ltd.), 
Sabouraud (SAB) and FANEO. Blood agar plates were used to establish the total enumeration 
of bacteria and identification of streptococci and staphylococci. CPS ID2, is a chromogenic 
media that enables the identification of E. coli, enterococci, Proteus and preliminary 
identification of Klebsiella, Enterobacter and Citrobacter; it was used to determine the 
presence of E. coli in samples. SAB plates were used to determine the presence of candida, the 
agar has a low pH that inhibits the growth of most bacteria; it also contains gentamicin to inhibit 
the growth of Gram-negative bacteria. FANEO agar was used to identify the presence of 







On receipt of the gastric aspirate in the laboratory, 50µL was directly plated onto whole plates 
of CPS ID2 and blood agar using a plastic hockey stick to make a lawn.  Serial dilutions of the 
aspirate to 10-1 and 10-2 were made and the plating repeated as above. The minimum detectable 
bacterial count was 20 CFU ml-1 and the maximum number of countable colonies was greater 
than 105 CFU ml-1.  If E. coli was presumptively identified, a representative number of isolates 
were selected for confirmation depending on the total colony count. Isolates were confirmed as 
E. coli by matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-
TOF) and confirmed as the Nissle strain by polymerase chain reaction (PCR). 
 
Oropharyngeal aspirates, Tracheal aspirates and Urine samples 
Oropharyngeal aspirates, tracheal aspirates and urine samples were all inoculated directly onto 
the four plates using a cotton swab. 
 
Rectal swabs 
Rectal swabs were plated out using a semi-qualitative technique on CPS-ID2, blood agar, and 
anaerobic plates.  At least 2 colonies of E. coli were selected for PCR analysis to look for the 
presence of E. coli Nissle.  
 
Bronchoalveolar lavage specimens 
BAL samples were processed using a standard operating procedure (SOP) in accordance with 
the SOP for the processing of BAL issued by the UK Health Protection Agency (HPA). 





out. The limit of detection using this technique is 2 x 103 CFU ml-1 and the maximum countable 
number is 2 x 106 CFU ml-1.  VAP is defined as growth of ≥ 104 CFU ml-1.  
 
All aerobic plates were incubated at 37°C in air and read at 24 hours and 48 hours. The 
anaerobic plates were read after 48 hours incubation in the anaerobic cabinet. Having noted the 
plate dilution, where necessary, the bacterial growth on the aerobic plates was described as 
follows: 
1. The qualitative appearance of the overall growth on the plate was recorded using the 
classification system in table 2.4 
2. The presence or absence of E. coli was noted, based on colony morphology, usually on 
the chromogenic plate. 
3. A qualitative assessment of the E. coli growth was made using the classification system 
in table 2.4 
4. The overall bacterial growth was reported as either pure or mixed, with the growth of 
the dominant species, if any, noted. If there was mixed dominance it was recorded as 
50:50 
5. Preliminary species identity was recorded using the chromogenic plate, and the presence 
of other species and growth noted. 
 
Growth Classification 
Scanty growth (visible individual colonies)  Very Light 
Lawn growth in primary inoculum Light 
Growth in primary and secondary inoculum Medium 
Growth in all quadrants of inoculum Heavy 
 





Representative colonies were saved from the blood and CPS-ID2 plates or sweeps of the 
original blood plates on beads. Multiple representatives of E. coli were saved depending on the 
number of colonies on the plate. These were grouped as 1, 2-5, 6-10 and >10 colonies with 1-
4 colonies saved respectively. 
 
For other species, one representative colony was saved for the dominant species. If there was a 
50:50 mix, a representative of each was saved. If the culture was a heavy mixed growth, a sweep 
from the original blood plate was saved. 
 
Yeast growth was classified as positive or negative classified according to the system in table 
2.4. No representative yeast colonies were saved. 
 
After the 24-hour read of the plates was completed, they were reincubated for a further 24 hours 
and read again.  Only changes from that of first read were recorded.  The plates were stored in 
the refrigerator and kept for comparison with the anaerobic plates, then discarded. 
 
The anaerobic plates were read after incubation for 48 hours. They were compared to the 
aerobic plates to help distinguish facultative anaerobes, which were not recorded, from obligate 
anaerobes. The bacterial growth on the anaerobic plates was described according to the system 









Overall Growth Anaerobic Pos/Neg Comments 
Qualitative comment on 
overall bacterial growth 
using classification in 
table 2.4 
Positive or Negative for 
presence of obligate 
anaerobes by colony 
morphology/odour 
Comment on 





Table 2.5 System for describing growth on anaerobic plates 
 
2.12 Identification of bacteria 
Identification of representative bacteria was carried out using matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS). MALDI-TOF 
MS is an accurate and rapid technique used for the identification of bacteria, fungi, and 
mycobacteria isolated in clinical microbiology. MALDI is an ionisation technique that uses a 
LASER energy-absorbing matrix to create ions from biological molecules. It is used as it tends 
to cause less fragmentation of large organic molecules than other ionisation techniques. A TOF 
mass spectrometer is used in conjunction with MALDI. In TOF MS an ion’s mass-to-charge 
ratio is determined by a time measurement following acceleration of the ion by an electric field 
of known strength. From this ratio, the identity of the molecule, and therefore bacteria, can be 
determined. 
 
2.13  Polymerase chain reaction assay for identification of Escherichia coli Nissle 1917 
A sample of E. coli Nissle strain was provided by Pharma-Zentrale (Ardeypharm) GmbH, 
Germany. This was used as a control for the Polymerase Chain Reaction (PCR) assay. Using 
the technique described by Blum-Oehler et al (225) the primer sets and amplicons in table 2.6 





Representative E. coli isolates from patient samples were tested to identify whether they were 
the E. coli Nissle strain. Bacterial DNA was extracted from culture and two PCR assays were 
performed.  The PCR assay targeted chromosomal and plasmid regions specific to the E. coli 
Nissle strain.  All of the strains identified as E. coli Nissle had the amplicons in table 2.6 
detected. 
 




Muta7 GACCAAGCGATAACCGGATG 427 bp 
Muta8 GTGAGATGATGGCCACGATT 
Muta9 GCGAGGTAACCTCGAACATG 313 bp 
Muta10 CGGCGTATCGATAATTCACG 
EcN1 GCATTCGCCCCAGAGGAATAA 400 bp 
EcN2 GTGTGCCTGAGACCCCAACAT 
   bp=base pairs 
Table 2.6 Primer Sets and DNA sequences used for PCR identification of E. coli Nissle 
 
 
2.14  Statistical analysis 
As this was an efficacy and dosing feasibility study, it was not designed or powered to detect a 
reduction in VAP; therefore, no sample size calculation was undertaken or this purpose. The 
sample size was based on a pragmatic approach working within the time, resource and financial 
framework available - as detailed in section 2.4. The sample size was, however, sufficient to 
detect gastric colonisation with E. coli Nissle.  
 
Using a primary comparison of control versus any E. coli Nissle dose, the study used a 1:2 





then 10 control vs 20 E. coli Nissle would detect an increase from 0.5% to 55% colonisation or 
more, assuming no loss to follow-up. There would be minimal power to detect any difference 
between the two doses – at 80% power a difference of 15% vs 85% would be needed to reach 
statistical significance. 
 
On reflection there was a limitation to this analysis plan. As this was a secondary exploratory 
analysis, it would have been more appropriate to use an analysis of variance (ANOVA) 
technique to analyse the data from the groups rather than within group analysis.  
 
Statistical analysis was performed using R Version 3.4.2 (R Core Team (2017). R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL https://www.R-project.org/). This was carried out as an intention to treat analysis. 
 
Continuous data were tested for normality by the Kolmogorov-Smirnov method.  Parametric 
data were analysed using a Student’s t-test for independent samples or paired t-test as the data 
dictated.  
 
Non-parametric data were analysed with Pearson’s Chi-squared test or a Wilcoxon Rank Sum 










2.15 Safety and adverse events management  
In compliance with the Medicines for Human Use (Clinical Trials) Regulations (2004) and 
current International Conference on Harmonization (ICH) guidelines on Good Clinical Practice 
(GCP), adverse events were monitored and recorded for the duration of patients’ participation 
in the study. 
  
An adverse event (AE) was defined as any untoward medical occurrence in a patient who was 
receiving the IMP, and which did not necessarily have a causal relationship to the treatment. 
Expected AEs were recorded on the case report form for each participant. These events were 
included as part of the safety analysis for the study only and were not required to be reported 
to the Sponsor. 
  
A serious adverse event (SAE) was defined as an adverse event that fulfils one or more of the 
following criteria: 
1)    Results in death 
2)    Is immediately life-threatening 
3)    Requires hospitalisation or prolongation of existing hospitalisation 
4)    Results in persistent or significant disability or incapacity 
5)    Results in congenital abnormality or birth defect (not expected in this patient population) 







Suspected Unexpected Serious Adverse Reactions (SUSARs) were defined as unexpected, 
serious events assessed by the sponsor and/or TMG as having a reasonable possibility of a 
causal relationship to the IMP and not consistent with the Summary of Product Characteristics. 
 
Patients recruited into the PECaN-ED study were already critically ill, therefore, it was 
expected that many of the participants would experience adverse events which would be 
expected in this patient population. Events that would be expected in this population, along 
with those that were collected as study outcomes, were not reported as SAEs. This included: 
1)    Death 
2)    Organ failure 
Patients were monitored for up to 30 days after the end of study intervention for any safety 
events (AE, SAE or SUSAR). Any SAEs or SUSARs that occurred between study recruitment 
and 30 days after the end of the study intervention were reported to the study sponsor in 
accordance with the sponsor’s safety reporting policy. 
 
SAEs and SUSARs were reported using the SAE form in the patient’s CRF, this was in 
accordance with Sponsor’s safety reporting policy. The Principal Investigator has a duty to 
report any SAEs and SUSARs to the sponsor within 24 hours of becoming aware of them. The 
Principal Investigator’s assessment of causality of SAEs (i.e. their relationship to trial 
treatment) is recorded on the Serious Adverse Event form. Subsequently, the Principal 
Investigator would be required to submit a full report on the resolution of the event. The sponsor 
is responsible for reporting suspected unexpected serious adverse events to the MHRA and 






If there had been any indication that the IMP was causing harm, or increasing the risk of harm 
to study participants, this would have been identified and the appropriate action taken. This 







































3.1 Recruitment and study participants 
The study took place on the Intensive Care Unit, Birmingham Heartlands Hospital, during the 
period 02/01/2013 until 12/12/2013 (figure 3.1).  
 
A total of 111 patients were screened for the study with 27 being enrolled (figure 3.2). The 
original target of 30 patients was not achieved due to time constraints and difficulties obtaining 
further supplies of E. coli Nissle 1917.  
 
The remaining 84 patients were not enrolled due to lack of consent from the personal consultee, 
consent not being obtained within 24 hours of commencement of mechanical ventilation, 
patients having exclusion criteria or clinician uncertainty about the requirement for mechanical 
ventilation for more than 48 hours.  
 
The expected duration of mechanical ventilation was determined by the treating consultant 
intensivist.  
 
A timeline for each patient is presented in appendix III. This details the clinical history, 
antibiotic therapy and acid suppression used as well as the timing of probiotic administration, 
















Figure 3.1 Recruitment period for PECaN-ED Study 
 
 
The horizontal lines represent the period for which each patient was in the study. The patient 
with study identification number 16 was the first to be recruited into the study due to an 





























*BREATHE Study - Protocolised trial of invasive and non-invasive weaning off ventilation  
 
Figure 3.2 Consort flow diagram for patient recruitment into PECaN-ED Study 
 
 
The setting for the study was a busy general, mixed medical-surgical ICU which does not accept 
major trauma or cardiac surgical patients. Taking this into account, the spectrum of reasons for 
ICU admission was representative of the normal ICU patient population for this unit. 
 
Patients were evenly distributed between groups based on age, sex and three different severity 
of illness scores (table 3.1). Statistical analysis was applied to the baseline data using a Welch 
T test using R (226). As the numbers involved in this feasibility study were small, statistical 
analysis was not applied to the groups for race, VAP risk factors or reason for ICU admission.  
111 Patients Screened 
27 Patients Randomised 
84 Excluded due to: - 
1. Inclusion/Exclusion Criteria 
2. Consent declined 
3. Unable to obtain consent 
within 24 hours intubation 
4. Treating clinician declined due 
to uncertainty about duration of 
mechanical ventilation 
 
8 Randomised to 5ml b.d. 
ECN 
10 Randomised to non-
treatment control 
9 Randomised to 15ml b.d. 
ECN 
 
Patients 7, 17 & 19 
ventilated for <48 hours  
 
Patient 14 - sampling 
discontinued at day 9 due 
to ESBL 
Patient 8 repatriated while 
still ventilated at day 9  
 
Patient 22 intermittently 
not receiving enteral 
nutrition  
 
Patient 23 failed extubation  
 
Patient 11 extubated day 5 
due to recruitment into 
BREATHE Study* 
 
Patient 26 - sampling 
discontinued at day 12 







 Control 5ml ECN 15ml ECN 
Total number of patients 10 8 9 
Female 6 5 3 




61.1 ± 12.1 
(41-75) 
APACHE II score ± SD (range) 21.0 ± 6.38 
(11-32) 
21.6 ± 4.41 
(15-30) 
24.3 ± 6.42 
(17-36) 




86.4 ± 13.97 
(68-112) 




47.3 ± 7.37 
(37-60) 
Race 
Caucasian 8 (80.0%) 7 (87.5%) 8 (88.9%) 
Asian 2 (20.0%) 0 (0.0%) 1 (11.1%) 
Afro-Caribbean 0 (0.0%) 1 (12.5%) 0 (0.0%) 
VAP risk factors 
Smoker 5 (50.0%) 6 (75.0%) 5 (55.6%) 
COPD 0 (0.0%) 1 (12.5%) 2 (22.2%) 
Chest trauma 0 (0.0%) 1 (12.5%) 0 (0.0%) 
Nursing home resident 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Alcohol abuse 2 (20.0%) 0 (0.0%) 2 (22.2%) 
Reason for ICU admission 
Trauma 0 (0.0%) 1 (12.5%) 0 (0.0%) 
Respiratory failure 
(including pneumonia) 4 (40.0%) 3 (37.5%) 3 (33.3%) 
Non-Resp Infection 2 (20.0%) 0 (0.0%) 1 (11.1%) 
Cardiology 3 (30.0%) 0 (0.0%) 4 (44.4%) 
Neurology 1 (10.0%) 2 (25.0%) 0 (0.0%) 
Gastrointestinal 0 (0.0%) 2 (25.0%) 1 (11.1%) 
  
 






3.2 Primary outcome 
The primary outcome of the study was to demonstrate gastric colonisation with E. coli Nissle. 
For the purposes of this study, colonisation was simply defined as the presence of E. coli Nissle 
in two consecutive gastric aspirates without a specific CFU threshold. The term colonisation is 
used variably in the literature and is generally taken to mean the presence of an organism 
without signs of associated infection. However, there is no universally accepted definition of 
colonisation with regard to the presence of an organism in the stomach, and the criteria used 
vary between publications. In the trial by Morrow et al (104), colonisation was simply taken to 
mean organism presence at a given time point.  
 
The trial by Garrouste-Orgeas et al offers a more detailed definition of gastric colonisation and 
considers colonisation as ICU-acquired only when there was no colonisation on admission and 
when the same potentially pathogenic microorganism was detected from at least two 
consecutive samples at a concentration ³102 CFU ml-1 (227). 
 
The results for E. coli Nissle colonisation in gastric aspirates are presented in table 3.2. 
Escherichia coli Nissle was not detected in any of the gastric aspirates from the control group. 
The bacteria would not have been expected to be present in this group, however cross-
contamination between treatment and control patient samples could have theoretically occurred 
during sample collection or handling. E. coli Nissle could have been present in a control group 
patient if that individual was carrying Nissle as a commensal organism. Again, this would have 






In the 5ml ECN group, colonisation was achieved in five of the eight patients studied (62.5%). 
In the 15ml ECN group, colonisation was achieved in seven of the nine patients studied 
(77.7%). The presence of E. coli Nissle was confirmed by PCR analysis of E. coli colonies.  
 
Therefore, based on these findings, it was possible to demonstrate gastric colonisation with E. 



















0 (0%) 7 (77.7%) 0.00045 
 







5 (62.5%) 7 (77.7%) 0.4902 
 
Table 3.2 Frequency of gastric colonisation with Escherichia coli Nissle in the 5ml and 








3.3 Secondary outcomes 
3.3.1 Dose variation and time to gastric colonisation 
Escherichia coli Nissle 1917 is marketed as Mutaflor® in Germany and is licensed for 
administration to infants, children and adults for a variety of indications. This is the first time 
that it has been administered to ventilated ICU patients. As such two different doses were 
selected to determine if this would affect gastric colonisation or time to gastric colonisation. 
 
Gastric colonisation was demonstrated in both the 5ml ECN and 15ml ECN treatment groups, 
however, there was no statistically significant difference between the two doses in terms of the 
number of patients colonised (p=0.4902) (table 3.2).  
 
The time to colonisation was measured in days, with the second consecutive day of E. coli 
Nissle presence in gastric aspirates signifying the time of colonisation. The period of time, in 
days, to colonisation was recorded for each patient. Although there was a tendency toward a 
shorter time to colonisation in the 15 ml ECN group (table 3.3), this was not statistically 











mean ± SD 
(range), days 
n/a 
5.6 ± 4.16 
(2-11) 










In the 5ml b.d. group, a sample on day four was not obtained for one of the patients. Had this 
sample been positive for E. coli Nissle, the time to colonisation for the 5ml b.d. group would 
have been reduced to 5.4 days. This result would not have altered the statistical significance 
between the two groups (p=0.22). 
 
3.3.2 Analysis of gastric aspirates 
Tables 3.4 and 3.5 show the detailed breakdown of the bacteria identified in the gastric aspirates 
at baseline and after 48 hours (all post 48-hour aspirates per study arm grouped together). The 
baseline aspirates were obtained at the earliest opportunity following enrolment and prior to 
administration of E. coli Nissle. Initial aspirates were obtained up to 24 hours post intubation 
depending upon the timing of consent.  
 
The overall proportion of gastric aspirates containing potential pathogens in the baseline group, 
including both Gram-positives and Gram-negatives was 59.2%. This was defined as gastric 
aspirates containing organisms with the potential to cause VAP.  
 
The bar charts in figure 3.3 show the relative proportions of organisms present in the combined 
baseline aspirates and the post 48-hour aspirates by study group. The proportion of Gram-
negative organisms remains relatively constant in the post 48-hour control and 5ml ECN groups 
(26.7% & 22.0% vs 22.2%). However, the proportion of Gram-negative organisms decreases 
to 4.3% in the 15ml ECN group. There is no statistically significant difference between the post 
48-hour 5ml ECN and control groups (p=0.58). There is, however, a statistically significant 
difference in the proportion of Gram-negatives between the post 48-hour 15ml ECN and control 





The overall proportion of potential pathogens in the gastric aspirates, both Gram-positive and 
Gram-Negative, is again relatively constant in the baseline and post 48-hour control and 5ml 
ECN groups (59.2%, 48.9%, 54.2%), decreasing to 15.2% in the post 48-hour 15ml ECN group. 
There was no significant difference between the post 48-hour control and 5ml ECN groups and  
baseline (p=0.39 and 0.66 respectively), however, there was a significant difference between 






 Control 5ml ECN 15ml ECN Total 
Number NG aspirates 10 8 9 27 
No growth 3 (30.0%) 1 (12.5%) 1 (11.1%) 
11 (40.7%) Skin flora (Coagulase-
negative Staphylococci/ 
Micrococci) 
1 (10.0%) 2 (25.0%) 3 (33.3%) 
Escherichia coli Nissle 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Non-Nissle Escherichia coli 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Other Coliforms 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Enterococci 0 (0%) 2 (25.0%) 2 (22.2%) 4 (14.8%) 
Streptococci 1 (10.0%) 0 (0%) 1(11.1%) 2 (7.4%) 
Staphylococci 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci 1 (10.0%) 1 (12.5%) 0 (0%) 2 (7.4%) 
Staphylococci/Corynebacteria 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci/ 
Enterococci 
1 (10.0%) 0 (0%) 0 (0%) 1 (3.7%) 
Staphylococci/Enterococci 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Streptococci/Enterococci 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Anaerobes 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Total Gram-Negatives 3 (30.0%) 1 (12.5%) 2 (22.2%) 6 (22.2%) 
Total Gram-Positives 3 (30.0%) 4 (50.0%) 3 (33.3%) 10 (37.0%) 
 







 Control 5ml ECN 15ml ECN 
Number NG aspirates 45 59 46* 




9 (20.0%) 3 (5.1%) 6 (13.0%) 
Escherichia coli Nissle 0 (0%) 17 (28.8%) 32 (69.6%) 
Non-Nissle Escherichia coli 10 (22.2%) 5 (8.5%) 1 (2.1%) 
Other Coliforms 2 (4.4%) 8 (13.6%) 1 (2.1%) 
Enterococci 4 (8.9%) 13 (22.0%) 2 (4.3%) 
Streptococci 4 (8.9%) 2 (3.4%) 0 (0%) 
Staphylococci 0 (0%) 1 (1.7%) 0 (0%) 
Staphylococci/Streptococci 1 (2.2%) 0 (0%) 0 (0%) 
Staphylococci/Corynebacteria 1 (2.2%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci/ 
Enterococci 
0 (0%) 0 (0%) 1 (2.1%) 
Staphylococci/Enterococci 0 (0%) 1 (1.7%) 2 (4.3%) 
Streptococci/Enterococci 0 (0%) 2 (3.4%) 0 (0%) 
Anaerobes 1 (2.2%) 0 (0%) 0 (0%) 
Total Gram-Negatives (Excl. 
Escherichia coli Nissle) 
12 (26.7%) 13 (22.0%) 2 (4.3%) 
Total Gram-Positives 10 (22.2%) 19 (32.2%) 5 (10.9%) 
*One aspirate excluded as unable to separate colonies 
 
 









Figure 3.3 Gastric colonisation in the probiotic and control groups (proportion of gastric 




























3.3.3 Analysis of oropharyngeal aspirates 
Oropharyngeal (OP) aspirates were obtained at baseline in the control group and before 
administration of E. coli Nissle in the treatment groups. Daily OP aspirates were obtained for 
the following three days and on alternate days thereafter. Results from the OP aspirate cultures 
were analysed and the proportion of potentially pathogenic species determined for combined 
baseline samples (table 3.6) and individual study groups for the subsequent samples (table 3.7). 
 
In the results from the combined baseline OP aspirates, the proportion of pathogenic Gram-
negative and Gram-positive potential pathogens is 25.9% and 55.6% respectively. The 
proportion of Gram-negatives remains relatively constant in the post 48-hour control and 15ml 
ECN groups but drops to 16.6% in the 5ml ECN group. There was no significant difference 
between the proportion of pathogenic Gram-negatives in the control, 5ml ECN or 15 ml ECN 






 Control 5ml ECN 15ml ECN Total 
Total OP aspirates 10 8 9 27 




0 (0%) 1 (12.5%) 1 (11.1%) 2 (7.4%) 
Escherichia coli Nissle 0 (0%) 0 (0%) 0 (0%) 0(0%) 
Non-Nissle Escherichia coli 1 (10.0%) 1 (12.5%) 2 (22.2%) 4 (14.8%) 
Other Coliforms 1 (10.0%) 0 (0%) 2 (22.2%) 3 (11.1%) 
Enterococci 2 (20.0%) 2 (25.0%) 1 (11.1%) 5 (18.5%) 
Streptococci 3 (30.0%) 0 (0%) 1 (11.1%) 4 (14.8%) 
Staphylococci 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci 0 (0%) 1 (12.5%) 0 (0%) 1 (3.7%) 
Staphylococci/Corynebacteria 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci/ 
Enterococci 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci/ 
Corynebacteria 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Enterococci 0 (0%) 0 (0%) 1 (11.1%) 1 (3.7%) 
Streptococci/Enterococci 2 (20.0%) 2 (25.0%) 0 (0%) 4 (14.8%) 
Anaerobes 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Bacilli (excluded from totals) 0 (0%) 0 (0%) 1 (11.1%) 1 (3.7%) 
Total Gram-Negatives (Excl 
Escherichia coli Nissle) 
2 (20.0%) 1 (12.5%) 4 (44.4%) 7 (25.9%) 
Total Gram-Positives  7 (70.0%) 5 (62.5%) 3 (33.3%) 15 (55.6%) 
 
 







 Control 5ml ECN 15ml ECN 
Total OP aspirates 46 45 46 




6 (13.0%) 5 (11.1%) 0 (0%) 
Escherichia coli Nissle 0 (0%) 3 (6.7%) 1 (2.2%) 
Non-Nissle Escherichia coli 7 (15.2%) 1 (2.2%) 2 (4.3%) 
Other Coliforms 5 (10.9%) 6 (13.3%) 9 (19.6%) 
Enterococci 3 (6.5%) 13 (28.9%) 7 (15.2%) 
Streptococci 3 (6.5%) 4 (8.9%) 7 (15.2%) 
Staphylococci 1 (2.2%) 1 (2.2%) 1 (2.2%) 
Staphylococci/Streptococci 1 (2.2%) 1 (2.2%) 0 (0%) 
Staphylococci/Corynebacteria 1 (2.2%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci/ 
Enterococci 
0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci/ 
Corynebacteria 
1 (2.2%) 0 (0%) 0 (0%) 
Staphylococci/Enterococci 0 (0%) 5 (11.1%) 1 (2.2%) 
Streptococci/Enterococci 2 (4.3%) 3 (6.7%) 3 (6.5%) 
Anaerobes 3 (6.5%) 1 (2.2%) 7 (15.2%) 
Bacilli (excluded from totals) 0 (0%) 0 (0%) 4 (8.7%) 
Total Gram-Negatives (Excl 
Escherichia coli Nissle) 
12 (26.1%) 7 (15.6%) 11 (23.9%) 
Total Gram-Positives  12 (26.1%) 27 (60.0%) 19 (41.3%) 
 
 






3.3.4 Analysis of tracheal aspirates 
A baseline tracheal aspirate was obtained for each patient prior to administration of the first 
dose of probiotic, followed by daily aspirates for the next three days and alternate days 
thereafter. An identical pattern of sampling was applied to the control group. The results from 
the baseline tracheal aspirates are shown in Table 3.8. Potential Gram-positive and Gram-
negative pathogens were demonstrated in 37.0% and 14.8% of combined baseline samples 
respectively. 
 
The results for the post 48-hour tracheal aspirates are shown for the three study groups in table 
3.9. Potential Gram-negative and Gram-positive pathogens persist through the three groups. Of 
note, there is a higher proportion of potentially pathogenic Gram-negative organisms in the 
15ml ECN group (28.9%) compared to baseline (14.8%) and compared to the 5ml ECN (9.4%) 
and control groups (19.4%). However, there is no statistically significant difference between 
the control, 5ml ECN or 15ml ECN and baseline (p=0.63, p=0.52 and p=0.18 respectively). 
 
Escherichia coli Nissle was detected in two tracheal aspirates from the treatment groups. This 
may represent sample contamination or possibly reflects the passive aspiration of gastric 






 Control 5ml ECN 15ml ECN Total 
Total tracheal aspirates 10 8 9 27 
No growth 3 (30.0%) 3 (37.5%) 1 (11.1%) 
8 (29.6%) Skin flora (Coagulase-
negative Staphylococci/ 
Micrococci) 
0 (0%) 0 (0%) 1 (11.1%) 
Escherichia coli Nissle 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Non-Nissle Escherichia coli 1 (10.0%) 0 (0%) 1 (11.1%) 2 (7.4%) 
Other Coliforms 0 (0%) 0 (0%) 2 (22.2%) 2 (7.4%) 
Enterococci 1 (10.0%) 1 (12.5%) 1 (11.1%) 3 (11.1%) 
Streptococci 4 (40.0%) 1 (12.5%) 0 (0%) 5 (18.5%) 
Staphylococci 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci 0 (0%) 1 (12.5%) 0 (0%) 1 (3.7%) 
Staphylococci/Corynebacteria 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci/ 
Enterococci 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Enterococci 0 (0%) 0 (0%) 1 (11.1%) 1 (3.7%) 
Streptococci/Enterococci 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Anaerobes 1 (10.0%)  2 (25.0%) 2 (22.2%) 5 (18.5%) 
Bacilli 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Total Gram-Negatives  1 (10.0%) 0 (0%) 3 (33.3%) 4 (14.8%) 
Total Gram-Positives  5 (50.0%) 3 (37.5%) 2 (22.2%) 10 (37.0%) 
 






 Control 5ml ECN 15ml ECN 
Total tracheal aspirates 36 32 38 
No growth 15 (41.7%) 15 (46.9%) 13 (34.2%) 
Skin flora (Coagulase-negative 
Staphylococci/ Micrococci) 
2 (5.6%) 3 (9.4%) 6 (15.8%) 
Escherichia coli Nissle 0 (0%) 1 (3.1%) 1 (2.6%) 
Non-Nissle Escherichia coli 5 (13.9%) 0 (0%) 3 (7.9%) 
Other Coliforms 2 (5.6%) 3 (9.4%) 8 (21.1%) 
Enterococci 3 (8.3%) 1 (3.1%) 2 (5.3%) 
Streptococci 2 (5.6%) 3 (9.4%) 1 (2.6%) 
Staphylococci 2 (5.6%) 1 (3.1%) 1 (2.6%) 
Staphylococci/Streptococci 2 (5.6%) 0 (0%) 0 (0%) 
Staphylococci/Corynebacteria 0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Streptococci/ 
Enterococci 
0 (0%) 0 (0%) 0 (0%) 
Staphylococci/Enterococci 0 (0%) 2 (6.3%) 1 (2.6%) 
Streptococci/Enterococci 1 (2.8%) 3 (9.4%) 0 (0%) 
Anaerobes 1 (2.8%) 0 (0%) 0 (0%) 
Bacilli (excluded from totals) 0 (0%) 0 (0%) 2 (5.3%) 
Total Gram-Negatives (Excl 
Escherichia coli Nissle) 
7 (19.4%) 3 (9.4%) 11 (28.9%) 
Total Gram-Positives  10 (27.8%) 10 (31.3%) 5 (13.2%) 
 







3.3.5 VAP, antibiotic days, ICU infection and surveillance data 
As this was the first time E. coli Nissle had been administered to an ICU population, regular 
surveillance samples were obtained for microbiological culture as part of the study protocol. 
The results of these samples were reviewed in conjunction with the routine clinical samples that 
were obtained (BAL, tracheal aspirate, blood cultures, wound swabs, catheter specimen urine, 
stool). 
 
Although the study was not powered to detect a reduction in the incidence of VAP, data were 
collected in order to determine the incidence of VAP in the study population. Based on the 
criteria described previously (section 2.10), six patients were diagnosed as having 
microbiologically confirmed VAP (table 3.10). Three of the study patients were mechanically 
ventilated for less than 48 hours, which gives a VAP incidence of 25%. In five of the six patients 
who developed a VAP, the causative organism was a Gram-negative species.  
 
ICU patients are frequently treated with multiple courses of broad-spectrum antibiotics. This 
reflects severity of illness, diagnostic uncertainty about source of infection or causative 
organism and concern about resistant species – particularly when the patient has had a 
prolonged stay on ICU or in in refractory multi-organ failure. 
 
Total antibiotic days, for both ICU stay and hospital stay, were calculated for the study patients 
as a comparison of overall antibiotic use in the three groups (table 3.11). Calculation of 
antibiotic days involves adding the number of antibiotics administered daily across all days 





for five days has a total of 15 antibiotic-days.  Incomplete administration is recorded as a 
fraction of the prescribed daily dose (i.e. 2 out of 3 doses is recorded as 0.66 for that day). 
 
 
Table 3.10 Details of study patients with microbiologically confirmed VAP 
 
The 5ml ECN group had the highest mean total antibiotic days for both ICU stay, and hospital 
stay (16.98 days (range 6.0-35.83), 24.13 days (range 6.5-77.93)). This is unlikely to be related 
to probiotic administration and it would be difficult to draw any firm conclusions as it represents 
such a heterogeneous group of patients. Furthermore, the data are likely to be skewed by 
outlying patients with multiple or prolonged courses of antibiotics. The data for total antibiotic 
days for ICU stay and hospital stay were analysed using a Wilcoxon Rank-Sum Test and no 
statistically significant difference any of the groups was identified (ITU: control vs 5ml ECN 
Study ID Group Diagnostic criteria Organism 
18 Control Fever, purulent secretions, 
inflammatory markers, CXR 
infiltrates 
Staphylococcus aureus  
20 Control Fever, purulent secretions, 
inflammatory markers, CXR 
infiltrates 
Escherichia coli 
6 5ml ECN Fever, purulent secretions, 
inflammatory markers, CXR 
infiltrates 
Enterobacter aerogenes 
13 15ml ECN Purulent secretions, 




26 15ml ECN Fever, purulent secretions, 
inflammatory markers, CXR 
infiltrates 
Escherichia coli 
28 15ml ECN Fever, purulent secretions, 







p=0.20; control vs 15ml ECN p=0.80; 15ml ECN vs 5ml ECN p=0.26), (Hospital: control vs 
5ml ECN p=0.15; control vs 15ml ECN p=0.81; 15ml ECN vs 5ml ECN p=0.09). 
 
Cumulative incidence of ICU-acquired infection was also measured as a secondary outcome. 
In addition to the six patients detailed above who developed VAP, four other episodes of ICU-
acquired infection were recorded. Two patients with indwelling urinary catheters developed 
culture positive urine with single organisms (patient 4 - E. coli, patient 19 - Citrobacter 
freundii).  
 
Patient 4 had a fully sensitive urinary E. coli. The patient was also found to be positive for E. 
coli Nissle in the stool and surveillance urine samples at the same time. Therefore, this may 
represent a contaminant, but in view of the diagnostic difficulties in ICU patients this was 
treated with a short course of antibiotics without further sequelae.  
 
Patient 24 (from the 15 ml ECN group) was treated for cellulitis of the left hand, which may 
have been related to a cannula site. No causative organism was identified for this infection. This 
is not likely to be related to the IMP but is included as part of the analysis of all ICU-related 
infection in the study population. 
 
Patient 27 (from the 15 ml ECN group) was initially admitted to ICU for renal support. He 
deteriorated and required intubation due to a hospital acquired pneumonia. Haemophilus 
influenzae and Pseudomonas aeruginosa were identified in tracheal secretions obtained post-
intubation. This would be classified as a HAP leading to respiratory failure requiring ventilatory 





Overall, the episodes described above represent an incidence of 40.0% for cumulative ICU-
acquired infection. 
 
Two patients (study ID 9,14 – both control group) were found to be positive for E. coli (blood 
and urine respectively) as part of their clinical presentation. Neither patient had any E. coli 
Nissle positive surveillance cultures and did not receive the IMP.  
 
Four patients (study ID 4,6,24,28) were found to have E. coli Nissle in culture of stool or rectal 
swab. Patient 6 was from the 5 ml ECN group; the other three patients were from the 15 ml 
ECN group. Patient 4 has already been discussed earlier in this section. Patient 6 had two E. 
coli Nissle positive surveillance urine cultures but no E. coli positive clinical urine cultures. 
Patients 24 and 28 were not found to have E. coli Nissle in any other surveillance cultures or 
E. coli in any clinical cultures.  
 
Supplementary secondary outcome data relating to duration of mechanical ventilation and 
length of ICU and hospital stay were collected (table 3.11). Although the study was not powered 
to detect difference in these outcomes, they are an excellent illustration of the heterogeneity of 
the ICU population which I have attempted to study, with wide ranges in all of these criteria 












*Patients who survived to ITU discharge; **Patients who survived to hospital discharge 
 
Table 3.11 Supplementary Secondary Outcome Data 
 
3.3.6 ICU, hospital and twenty-eight day mortality 
Eleven of the patients in the study died within 28 days of ICU admission (table 3.12). Ten 
patients died while on ICU and one patient died following ICU discharge. The death of this 
patient was expected. Deaths came from all three trial groups – 4 patients (control), 2 patients 
(5ml ECN), 5 patients (15 ml ECN).  
 
The causes of death for these patients are listed in table 3.13. The causes of death were diverse 
although it is notable that 5 of the deceased patients were from the 15ml ECN group. None of 
the causes of death were linked in any way to the administration of probiotic. Patient 6 did die 
due to the complications of small bowel ischaemia. This is worthy of mention as it was the 
 Control 5ml ECN 15ml ECN 
Mean/Median duration 







Mean ICU LOS in days* 
(range)  
12.7 (1.6-46.0) 15.1 (5.5-29.8) 11.8 (6.1-24.3) 
Median ICU LOS in 
days*  7.0 13.1 8.0 
Mean Hospital LOS in 
days** (range)  34.3 (4.0-79.0) 32.0 (10.0-53.0) 30.8 (11.0-68.0) 
Median Hospital LOS in 
days**  19.5 31.0 22.0 
Mean abx days (ICU) 
(range) 10.06 (0-35.0) 16.98 (6.0-35.83) 8.92 (0-17.83) 
Mean total abx days (incl 





cause of excess deaths in the treatment group patients from the PROPATRIA trial (168). This 
was not felt to be linked to probiotic administration as it was noted at time of surgery that the 
small bowel changes appeared to be chronic rather than acute. 
 
 Control 5ml ECN 15ml ECN 
28 Day Mortality (% by group) 4 (40%) 2 (25%) 5 (55.5%) 
 
Table 3.12 Twenty-eight Day Mortality by Group 
 
Four SAEs were reported to the trial sponsor by the research team. Three of these patients died 
(study ID 3, 6, 26) and as discussed, the deaths were not related to the IMP. The fourth patient 
(study ID 23) deteriorated two days after extubation and required re-intubation due to septic 
shock and cardiovascular instability. This was not related to the IMP and the patient survived 










Study ID Study Group Cause of Death 
7 Control 
i. Hypoxic-ischaemic encephalopathy 
ii. Cardio-respiratory arrest 
iii. Acute myocardial infarction 
15 Control i. Paraneoplastic encephalitis 
ii. Metastatic lung cancer 
18 Control 
i. Left ventricular failure 
ii. Ischaemic heart disease 
20 Control 
i. Hypoxic-ischaemic encephalopathy 
ii. Hypoxic Cardiac arrest 
iii. Fall -> C1/2 fracture 
6 5ml ECN 
i. Small bowel ischaemia 
ii. Bleeding duodenal ulcers (chronic) 
iii. Traumatic broncho-pleural fistula 
12 5ml ECN 
i. Respiratory failure 
ii. H1N1 Pneumonia 
iii. Laparotomy for small bowel obstruction 
3 15ml ECN i. Myocardial infarction secondary to S. aureus endocarditis 
ii. H1N1 Pneumonia 
11 15ml ECN 
i. Septicaemia 
ii. Empyema 
iii. End stage renal failure 
24 15ml ECN 
i. Hypoxic-ischaemic encephalopathy 
ii. Cardio-respiratory arrest 
iii. Acute myocardial infarction 
26 15ml ECN 
i. Respiratory failure 
ii. Hospital acquired pneumonia 
iii. Severe critical illness polyneuropathy 
iv. COPD 
28 15ml ECN 
i. Multi-organ failure 
ii. Cardiac arrest 
iii. Ischaemic heart disease 
 






A Kaplan-Meier plot (figure 3.4) was compiled for all treatment patients versus control. This 
demonstrated no significant difference between the survivorship curves.  This was carried out 
using R with a total sample size of 27 patients and a Chi-square value of 0.09 with one degree 
of freedom, giving a p-value of 0.76.  
 
 












3.3.7 Administration and sampling 
Obtaining NG aspirates is not without technical difficulty and the presence of a nasogastric tube 
does not guarantee that a sample can be obtained. It can also be a time-consuming process. 
Despite the difficulties of NG sampling 180 samples were obtained out of 186 planned samples. 
Sampling was discontinued electively in two patients, one from the control group (study ID 14) 
and one from the 15ml b.d. group (study ID 26), as it was felt unlikely to yield further useful 
results. 
 
As a surrogate measure of colonisation, a best fit line was drawn between the number of ECN 
doses administered and the number of ECN positive NG aspirates for both treatment groups, 
using the Least Square method. This shows a positive correlation between duration of dosing 
and number of ECN positive gastric aspirates for the 15 ml ECN group and a weakly positive 













Figure 3.5 Lines of best fit for number of ECN doses administered and number of positive 




























4.1  Discussion 
Hospital acquired infections continue to present a significant challenge to healthcare 
professionals worldwide. In England, there are approximately 100,000 HAI’s per year which 
lead to approximately 5,000 deaths and have a significant financial impact on the NHS – an 
institution already under enormous strain. Approximately 25% of these occur in ICU patients 
and arise as a complication of critical illness. Hospital acquired infections in the critically ill 
population have been the focus of much attention in recent years, in particular, ventilator 
associated pneumonia.  
 
Up to 30% of ICU patients develop a ventilator associated pneumonia, increasing length of 
stay, morbidity, mortality and cost. VAP is a nosocomial pneumonia that develops more than 
48 hours after tracheal intubation and mechanical ventilation (8). VAP occurs because 
potentially pathogenic bacteria from the sinuses, oropharynx, subglottis and gastrointestinal 
tract gain access to the bronchial tree. This is facilitated by the presence of the tracheal tube, 
which allows microaspiration of secretions and biofilm formation, by-passing the body’s 
natural defences (9). The elegant study by Garrouste-Orgeas et al examines the relative 
contribution of gastric and oropharyngeal colonisation and the role of these organisms in the 
development of VAP (227).  
 
Although there is no doubt about the importance of VAP and its sequelae, it is a diagnosis that 
exists without a clear consensus definition. It is based on a combination of clinical, radiological 
and microbiological criteria but no combination of these has, thus far, been felt to offer enough 
diagnostic accuracy or confidence to justify their use its definition. The lack of a universally 





monitor incidence, make meaningful comparisons of studies into prevention and in examining 
the implementation of these techniques. 
 
Khan et al make an interesting observation about the term itself, “ventilator associated 
pneumonia” (228). The term suggests a casual rather than causal association between invasive 
ventilation and VAP. The authors argue that VAP conveys an almost incidental relationship 
between invasive ventilation and the development of pneumonia. In fact, ventilation is really 
the “driving force” behind the pathology and a more accurate and appropriate term would 
perhaps be “ventilator induced pneumonia”.   
 
The vast majority of cases of VAP are bacterial in origin, with approximately 60% of organisms 
being Gram-negative. Fungal and viral VAP can occur but their relevance and pathogenesis are 
unclear (22).  
 
The organisms commonly associated with VAP are detailed in table 4.1 which is taken from 
the 2002 publication by Chastre and Fagon (22).  The organisms were isolated by 
bronchoscopic techniques in 24 international studies over the period 1989-2000. These data 
may give the impression that VAP is caused by a single organism, when in fact it may be 
polymicrobial. 
 
There is a paucity of data from the UK regarding national VAP rates and causative organisms. 
Data from Scottish ICUs is presented in the Intensive Care Unit Associated Infection National 





episodes of HAP were examined, 91.5% of which were VAP. The distribution of organisms is 
shown in figure 4.1. 
 
 
Figure 4.1 Distribution of organisms isolated from cases of pneumonia from Scottish ICUs 
(229) 
 
There are some parallels with the international data shown in table 4.1, with Staphylococcus 
aureus and Pseudomonas aeruginosa being the predominant species in both series. 
Interestingly, Candida species appear to be much more prominent in the Scottish data. 
 
An important factor when considering the likely causative organism or organisms in VAP is 
the duration of mechanical ventilation. An episode of VAP that develops within four days of 
the commencement of invasive ventilation is likely to be caused by a community acquired 
organism, for example, Haemophilus species, Streptococcus pneumoniae or methicillin 
sensitive Staphylococcus aureus. Episodes of VAP developing after this time are more likely 
to be caused by multi-drug resistant species such as Pseudomonas aeruginosa, Acinetobacter 





contact with the healthcare system or environment, for example, regular attendance at a 
haemodialysis unit or being resident in a nursing home. These patients are more likely to 
develop infections with multidrug resistant bacteria (11). 
 










Enterobacteriaceae* Negative 14.1 
Haemophilus species Negative 9.8 
Staphylococcus aureus † 
 
Positive 20.4 




Coagulase-negative staphylococci Positive 1.4 
Neisseria species Negative 2.6 
Anaerobes n/a 0.9 
Fungi n/a 0.9 
Others (<1% each) ‡  n/a 3.8 
 
* Distribution when specified - Klebsiella 15.6%; E. coli 24.1%; Proteus 22.3%; Enterobacter 18.8%; 
Serratia 12.1%; Citrobacter 5.0%; Hafnia alvei 2.1% 
† Distribution when specified - methicillin-resistant S. aureus 55.7%; methicillin-sensitive S. aureus 
44.3% 
‡Including Corynebacterium, Moraxella, and Enterococcus 
 
Table 4.1 Distribution of organisms isolated from cases of ventilator associated 







The organisms associated with VAP on a given ICU will also depend on the case mix and nature 
of admissions, the hospital itself and patient comorbidities (22). As part of good institutional 
antibiotic stewardship, it is essential to monitor the profile of organisms associated with VAP 
to ensure that the most appropriate empirical antibiotic therapy is used. 
 
As described above, the bacteria responsible for the development of VAP are predominantly 
Gram-negative, and with growing concerns about the rise of multidrug-resistant strains, we 
must try to move away from reliance on antimicrobials for the treatment of VAP and continue 
to explore non-antibiotic strategies in its prevention.  
 
Prevention of VAP is a significant part of ICU “housekeeping” and its importance is highlighted 
by the guidance from the National Institute for Health and Clinical Excellence. Although much 
emphasis is placed on this, many studies looking at strategies and interventions to reduce VAP 
incidence fail to demonstrate convincing clinical benefit in terms of duration of mechanical 
ventilation, length of ICU admission or mortality. This is undoubtedly, at least in part, linked 
to the difficulties of accurate diagnosis discussed before. 
 
VAP prevention strategies focus on three areas – reducing colonisation of the aerodigestive 
tract with potentially pathogenic organisms, prevention of aspiration into the bronchial tree and 
minimisation of the duration of mechanical ventilation.  
 
With the focus on the microbiological aspects of VAP, it is easy to overlook the deleterious 
effect of invasive ventilation on the capillary endothelium, epithelium and basement membrane 





pneumonia. However, in terms of modifiable risk factors, manipulation of the microbiological 
milieu of the aerodigestive tract is a strategy that may yield more immediate results, hence the 
consideration of probiotic therapy in this quest. 
 
Although the mechanisms underlying the putative protective effects of probiotics in critically 
ill patients remain to be elucidated, there is evidence that probiotics could inhibit colonisation 
of pathogenic bacteria and enhance immunity. It is clear that there are multiple mechanisms by 
which different probiotic bacteria may exert their effects and these effects vary with the strain 
and population studied (230).  
 
The Cochrane systematic review, Probiotics for preventing ventilator-associated pneumonia, 
by Bo et al found that probiotics significantly reduced the incidence of VAP (184). In the per-
protocol analysis of probiotics versus control and their effect on incidence of VAP eight 
relevant trials were analysed. There was a significant difference between various probiotic 
treatments and their respective control groups for the incidence of VAP (p=0.02, OR 0.70, 95% 
CI 0.52-0.95), albeit from evidence graded as low quality.  
 
Interestingly, despite the range of beneficial effects which appear to be offered by probiotics in 
individual studies, the systematic review did not demonstrate any additional benefit in terms of 
the other outcomes measured - ICU mortality, in-hospital mortality, incidence of diarrhoea, 
length of ICU stay, duration of mechanical ventilation or antibiotic use. 
 
As the ICU population is relatively immunocompromised, it was felt that these patients may be 





There were no reports of any nosocomial probiotic infections in the included studies (184). In 
making this observation, one must be cognisant of the fact that outcomes such as adverse events, 
duration of mechanical ventilation and antibiotic use, were underreported in many of the 
studies, making it difficult to draw firm conclusions even from the Cochrane review. 
 
Bo et al’s main findings are in agreement with the previous meta-analyses by Siempos et al 
(186) and Petrof et al (195), but contradicted the results of the meta-analysis by Gu et al (196). 
There were several important differences between these meta-analyses which were highlighted 
and discussed in section 1.5.5, all of which lends weight to the argument for an adequately 
powered and methodologically sound study of the use of probiotics in the context of VAP 
prevention.  
 
The existing evidence for the beneficial effects of probiotics in a range of clinical situations, 
coupled with the lack of a consistent message from the studies on probiotic prevention of VAP, 
lead our group to discuss the use of a single probiotic species in a feasibility study in the ICU 
population.  
 
Escherichia coli Nissle 1917 was selected as it had already been studied extensively in other 
contexts and had an excellent safety record.  In addition to its immunomodulatory effects, E. 
coli Nissle is known to possess strain-specific characteristics which enable it to readily colonise 
the gut and inhibit colonisation by other Gram-negative organisms, specifically 
Enterobacteriaceae. We suggested that administration of E. coli Nissle to invasively ventilated 
ICU patients had the potential to reduce or eliminate gastric colonisation by pathogenic Gram-





proposed that twice daily nasogastric administration of 5 ml or 15 ml of E. coli Nissle 
suspension to invasively ventilated ICU patients would lead to successful gastric colonisation 
by this species, and significantly reduce ICU acquired gastric colonisation by pathogenic Gram-
negative bacteria compared to non-treatment controls.  
 
The group had previously demonstrated successful bacterial culture from 20 gastric aspirate 
specimens (unpublished data). Eleven patients were included in this group, with a median 
duration of mechanical ventilation of 7.5 days.  These samples were collected from 11 patients, 
10 of whom had been treated with broad-spectrum antibiotics. Bacterial colonisation was 
demonstrated in 95% of specimens with 50% having a heavy growth of Gram-negative bacteria, 
and 45% having a moderate growth of Gram-positive bacteria. This demonstrated that culture 
of gastric aspirates was possible with standard microbiological techniques in our laboratory and 
was an acceptable method of demonstrating gastric colonisation in a feasibility study.  
 
Based on the historical admission data from our ICU as detailed in section 2.4, we anticipated 
recruiting 3 patients per month into the study. We failed to reach our recruitment target by the 
end of 12 months and due to time constraints and the logistical difficulties of obtaining the 
probiotic via a third-party importer, it was decided by the group to terminate the study at this 
point.  
 
The likely duration of mechanical ventilation (>48 hours or not) was determined by the treating 
consultant of the day. Of the 27 patients recruited, three were ventilated for less than 48 hours 





prediction of duration of mechanical ventilation is unreliable, particularly in the early part of 
the admission  and this was a drawback of the study (220). 
 
None of the patients recruited to this study was a planned admission. Planned admission of an 
invasively ventilated patient is uncommon in our ICU. Therefore, all of the patients in the study 
were unplanned or emergency admissions. This posed a degree of difficulty as patients had to 
be recruited within 24 hours of intubation, and hence we were unable to recruit some admissions 
which occurred out of hours or at weekends.  
 
During the PECaN-ED study, one patient (study ID 11, 15ml ECN group) was also enrolled 
into the treatment arm of another study looking at weaning from mechanical ventilation. This 
resulted in an earlier than anticipated extubation. It is difficult to determine if this would have 
had any implication for the results obtained, however, it would be an important consideration 
for co-enrolment in any future studies. 
 
As with any trial involving ICU patients, consent was ideally obtained from a personal legal 
representative. Again, due to the timing of unplanned or emergency admissions and the 
necessity to recruit within 24 hours of intubation, we did encounter come difficulties in 
obtaining consent from personal legal representatives in a timely fashion.  
 
Although consent was declined in some instances, this was in a minority of cases and, in 
general, the study was well received by the personal legal representatives we approached. 
Although it was clearly explained that the use of probiotics in ICU patients was a relatively 





many people making reference to commercially available probiotics and expressing a genuine 
interested in the proposed benefits and potential mechanism of action in ICU patients. 
 
It is important to acknowledge the contribution of the ICU nursing staff both in terms of 
probiotic administration and sample collection. Training on the study was delivered to assist 
the nurses in this role. As an investigational medicinal product (IMP), the probiotic suspension 
was kept in a locked refrigerator, administered twice daily and required a two person check for 
administration. This did impose to some extent on the ICU nurse workload and their help in 
administration was greatly appreciated.   
 
Both administration of the probiotic suspension and sample collection had to be done with a 
great deal of care due to the possibility of cross contamination. The probiotic was presented as 
a concentrated suspension of bacteria which, if not handled carefully, could have contaminated 
other research or clinical samples.  
 
Obtaining gastric aspirate samples from nasogastric tubes at times proved difficult. Although 
gastric aspirates are measured routinely as part of ICU care – to determine if the patient is 
absorbing enteral feed – they are not always readily obtained. If it was not possible to aspirate 
gastric contents freely from the nasogastric tube, a number of techniques were tried in order to 
facilitate this. These techniques included waiting for 20-30 minutes and re-attempting 
aspiration, tilting the patient to the left and/or right-hand side and re-attempting aspiration, or 
instilling 10-20 millilitres of normal saline and then re-attempting aspiration.  If the sample was 





microbiological processing took place. Despite these difficulties, 180 out of 186 planned 
samples were obtained. 
 
Prior to the discovery of Helicobacter pylori in 1982, the stomach had been regarded as a 
“sterile” environment, inhospitable to bacteria due to acid production, peristaltic activity, thick 
mucus layer and the presence of bile acids from the small intestine. The difficulties in obtaining 
samples and the limited techniques available for analysis also hampered study of the gastric 
microbiome. However, the discovery that acid-resistant strains of bacteria were present in the 
stomach, together with the advent of a range of culture-independent molecular techniques based 
on 16S rRNA gene sequencing, has led to renewed interest in the gastric microbiota in health 
and disease (231). 
 
In recent years molecular techniques have been used to analyse the gastric mucosa and 
microbiota of small groups of healthy volunteers. The microbiota is obviously affected by 
dietary intake, medication, mucosal inflammation and H. pylori effect but, at a phyla and genera 
level, appears to be surprisingly similar between races (232–235)o. 
 
With regard to the gastric microbiota in the ICU population, factors of particular relevance are 
the use of broad-spectrum antibiotics and gastric acid suppression. Gastric acid suppression 
with either PPIs or H2RAs can significantly alter the profile of the gastric microbiota. Bacterial 
overgrowth in the stomach will occur when the gastric pH>3.8 (236); anecdotally, many of the 
gastric aspirates in the ICU population are approximately pH 6.0. Use of antibiotics will also 





cephalosporin has been shown to cause a significant reduction in the number of Lactobacilli 
and overgrowth of Enterococci (237). 
 
Although molecular techniques are becoming the norm in the exploration of the microbiological 
profiles of various physiological environments, the stomach of the ventilated ICU patient 
remains a relatively uncharted territory, although some work has been done on the intestinal 
bacterial composition of these patients (238).  
 
The technique used previously to investigate gastric colonisation in patients relied on traditional 
culture-based methods. These have been reproduced in a number of studies; the assumption 
being that the presence of an organism on gastric culture signifies colonisation 
(104,128,171,189). However, as over 80% of microorganisms are non-culturable, the 
identification of bacterial species by conventional methods provides an incomplete and not 
unbiased view of the gastric microbiota. Furthermore, the study of gastric aspirate fluid alone 
does not allow us to consider the bacterial colonisation of the gastric mucosa. This not only 
overlooks the presence of specific organisms, but fails to take into account bacterial-host cross-
talk (231). 
 
The PECaN-ED study was carried out prior to the current Intensive Care Society 
recommendations on the use of stress ulcer prophylaxis as part of the ventilator care bundle (9) 
and the widespread use of both PPIs and H2RAs is clearly shown in the individual patient 
timelines in appendix III. Although previously considered a relatively innocuous therapy, the 
impact of acid suppression may be more far-reaching than first anticipated. While detailed 





aspects of this: There are acid-producing cells throughout the upper aerodigestive tract in 
humans, the impact of acid suppression on which is unclear; PPIs will have an effect on 
naturally occurring gut bacteria which possess the H+/K+-ATPase pump; and the gastric 
microbiota will be altered as a result of the change in pH (236). 
 
Colonisation of the airway is an essential step in the development of a VAP as a result of 
microaspiration of gastric or oropharyngeal colonised with potentially pathogenic organisms 
(32). The term colonisation is widely used in related literature but is infrequently and variably 
defined. The trial by Garrouste-Orgea et al uses precise definitions of colonisation and 
infection: Colonisation at the time of ICU admission was defined as the isolation of at least one 
microorganism from the oropharynx and/or stomach at a concentration of ≥102 CFU ml-1 within 
the first 48 hours of admission. Colonisation was considered to be ICU-acquired only when 
there was no colonisation on admission and when the same potentially pathogenic 
microorganism at a concentration of ≥102 CFU ml-1 was detected from at least two consecutive 
samples from the same site (227). In contrast, Morrow et al used presence of an organism at a 
single time point to define colonisation (104).  
 
In the trial by Garrouste-Orgea et al the diagnosis of VAP was made using the association of 
clinico-radiological criteria and a positive quantitative culture ≥103 CFU ml-1 (protected 
specimen from plugged catheter or telescopic brush catheter). When protected samples were 







Using culture-based techniques for determination of gastric colonisation, we demonstrated 
gastric colonisation with E. coli Nissle in those patients whom had received the IMP. The 
technique used does have certain drawbacks, primarily the assumption that the presence of E. 
coli Nissle, without quantification, in two consecutive gastric aspirate samples represents 
colonisation. This may only represent a transient population of E. coli Nissle in the stomach or 
that the stomach is effectively acting as a “sump” of E. coli Nissle which is simply being 
sampled periodically. It also overlooks the effect at a mucosal level and gives no indication of 
bacterial-mucosal interaction or potential mucosal colonisation.  
 
We are also, of course, making the assumption that true colonisation is actually necessary for 
the probiotic organism to exert a beneficial effect - some benefit may come simply from the 
presence of the probiotic organism in the stomach due to regular administration via the 
nasogastric tube.  
 
Another potential drawback of this sampling technique is the risk of biofilm formation on the 
internal surface of the nasogastric tube. This poses the risk that sampling and administering 
though the same lumen may lead to false positive results. The counter-argument to this is that 
study patients were all receiving enteral nutrition, and the continuous delivery of feed via the 
nasogastric tube should mitigate against this.  
 
It is, nevertheless, an interesting achievement that we were able to demonstrate the presence of 
culturable E. coli Nissle in an, albeit acid-suppressed, non-native environment with a high 






In the analysis of gastric aspirates, the predominant species was identified at baseline and after 
48 hours. The proportion of Gram-negative organisms remained relatively constant in the post 
48-hour control and 5ml ECN groups (26.7% & 22.0% vs 22.2%). However, the proportion of 
Gram-negative organisms decreased to 4.3% in the 15ml ECN group. A statistically significant 
difference in the proportion of Gram-negatives was identified between the post 48-hour 15ml 
ECN and control groups (p<0.01), and post 48-hour 15ml ECN and 5ml ECN groups (p=0.01). 
The overall proportion of potential pathogens in the gastric aspirates, both Gram-positive and 
Gram-Negative decreased to 15.2% in the post 48-hour 15ml ECN group, which represented a 
significant difference between the 15ml ECN group and baseline (p<0.01). 
 
This appears to show that, after 48 hours, in the higher dose group E. coli Nissle was becoming 
the predominant species in the gastric aspirate samples, both in terms of Gram-negatives and 
overall species. The reasons for this may include out-competing other bacteria or a direct effect 
on other bacteria such as bacteriocin production - the microcins M and H 47 produced by E. 
coli Nissle could help it compete against bacteria that utilise catecholate siderophores such as 
the Enterobacteriaceae (239). Escherichia  coli Nissle may also out-compete pathogenic 
bacteria for essential nutrients (240). 
 
In the analysis of the OP aspirates, there was no significant difference between the proportion 
of pathogenic Gram-negatives in the control, 5ml ECN or 15 ml ECN groups compared to 
baseline (p=0.99, p=0.28 and p=0.85 respectively). At the time of this study, chlorhexidine gel 
was still being routinely used orally as part of the ICU ventilator care bundle. This is no longer 
a recommendation in the general ICU. Although samples OP samples were collected prior to 





The results for the post 48-hour tracheal aspirates showed that potential Gram-negative and 
Gram-positive pathogens persisted through the three groups but, interestingly, there was a 
higher proportion of potentially pathogenic Gram-negative organisms in the 15ml ECN group 
(28.9%) compared to baseline (14.8%) and compared to the 5ml ECN (9.4%) and control 
groups (19.4%). There was no statistically significant difference between the control, 5ml ECN 
or 15ml ECN and baseline, however, this relative increase in potential Gram-negative 
pathogens did occur despite a significant reduction in the Gram-negatives in the gastric 
aspirates. It does emphasise that we have an over-simplistic view of the mechanisms at play in 
the development of VAP. Escherichia coli Nissle was detected in two tracheal aspirates from 
the treatment groups, which may represent the expected passive aspiration of gastric contents 
into the bronchial tree. 
 
Commercially, E. coli Nissle is available as lyophilised bacteria in an enteric coating, with each 
capsule containing 2.5-25 x 109 CFU. The recommended adult dose is 2 capsules per day (up 
to a maximum of 4 capsules per day) for chronic constipation or maintenance of remission in 
ulcerative colitis. Each millilitre of the suspension contains 1x108 CFU, therefore the doses 
administered in this study were 5 x 108 b.d. or 1.5 x 109 b.d. 
 
Using these doses, we were unable to demonstrate a significant difference in the number of 
patients colonised or the time to colonisation. As no adverse outcomes were demonstrated, a 
higher dose could be considered for use in future studies. 
 
The study was not powered to detect a reduction in the incidence of VAP, however, six patients 





the study population of 25%. In five of the six patients who developed VAP, the causative 
organism was a Gram-negative species.  
 
Interestingly, three of the VAP patients (study ID 13, 26, 28) were from the 15ml ECN study 
group. Of the other three VAP patients, two were from the control group (study ID 18, 20) and 
one was from the 5ml ECN group (study ID 6) (table 3.10). The two patients (20, 26) who 
developed an E. coli VAP were negative for E. coli Nissle in all surveillance cultures.  
 
Patient 13 (from the 15ml ECN group) had a single tracheal aspirate in the study samples which 
was positive for E. coli Nissle. Escherichia coli was not cultured in any of the clinical tracheal 
aspirates.  
 
Patient 6 (from the 5ml ECN group) also had a single tracheal aspirate in the study samples 
which was positive for E. coli Nissle. Again, E. coli was not demonstrated in any of the clinical 
tracheal aspirates. 
 
4.2  Limitations 
Escherichia coli was identified in a number of clinical samples, as discussed at the end of 
section 4.1. In only one case did this possibly represent an E. coli Nissle contaminant which 
had clinical significance. To avoid the possibility of E. coli Nissle inadvertently being treated 







By definition, patients enrolled into the study were receiving enteral nutrition. However, this is 
not without interruption, due to factors such as confirmation or re-confirmation of nasogastric 
tube position, interruptions to feeding for patient transfer or alteration of enteral feed 
administration rate due to patient specific factors such as problems with absorption. These 
factors were not recorded as part of the study protocol and could conceivably have had an effect 
on the host-probiotic interaction. 
 
A number of the study patients were already admitted to hospital prior to coming to ICU. 
Changes that may have already taken place in their gut flora due to illness, antibiotic exposure 
or acid suppression will not have been accounted for in this study. This is a further argument in 
favour of trials using trauma patients as the population studied, as they will generally be 
admitted directly from the community avoiding prior hospital admission as a potential 
confounding factor. 
 
4.3  Future work 
It is recognised that ICU admissions due to trauma are an independent risk factor for the 
development of VAP (20). In the U.S. the National Healthcare Safety Network (NHSN) data 
show that VAP rates for trauma patients are consistently two to three times higher than the 
general ICU population. The International Nosocomial Infection Control Consortium (INICC) 
has shown similar results from the developing world. The INICC report from 2004–2009 
showed a VAP rate of 40.0 per 1000 ventilator days in trauma patients, with a corresponding 
rate of 15.8 per 1000 ventilator days in ICU patients overall. This was also demonstrated in the 
EU-VAP study with trauma being associated with a higher risk of developing VAP (OR 2.89, 





population, it may be an appropriate population on which to focus probiotic studies in the future. 
The Cochrane Review by Bo et al also highlighted this saying, “there may be a strong rationale 
for the use of probiotics in trauma patients. Studies in this group of patients showed a significant 
reduction in the incidence of VAP as well as improved survival”. In addition, the severity of 
injury may predict a more prolonged period of invasive ventilation. 
 
There is conflicting opinion regarding the attributable mortality due to VAP. Some studies 
suggest that the attributable mortality is low and that this should be taken into account when 
using mortality as an end point or when using superiority studies. Outcome measures such as 
duration of ICU stay, hospital say and mechanical ventilation would appear to be more relevant 
and more consistently influenced by VAP (28). 
 
Work has been carried out examining the concentration of antibiotics in gastric secretions and 
gastric mucosa. Although this has largely been in relation to the antibiotics used for the 
eradication of H. pylori, and also the effect of omeprazole on these, some interesting 
observations have been made. For example, metronidazole and erythromycin are secreted 
across the gastric mucosa but ampicillin is not; omeprazole decreases the intragastric 
concentrations of metronidazole but increases the intragastric concentrations of amoxicillin 
(242,243). The widespread use of broad-spectrum antibiotics in ICU patients may have an 
incidental effect on probiotics administered via the nasogastric route, yet this is an area that 
requires further investigation.  
 
Some simple interventions may aid future study and help with the difficulties of gastric aspirate 





contamination and make handling easier. Use of a double-barrelled nasogastric tube would 
allow one port for feeding and administration of probiotic and a dedicated port for sampling. 
This may make sampling more straightforward and would also reduce the chance of 
contamination of the aspirate by any biofilm formation on the inside of the nasogastric tube. 
 
In our study, Escherichia coli Nissle was administered at the lower end of its dose range and a 
tendency toward a shorter time to colonisation in the higher dose 15 ml ECN group was 
demonstrated. Further studies using different dose ranges may therefore be warranted. 
 
The methods used to date for determining gastric colonisation are culture-based. In our study 
we used two consecutive gastric aspirate samples positive for E. coli Nissle to signify 
colonisation. Previous studies have simply used the presence of the probiotic in question in the 
gastric aspirate as evidence of gastric colonisation. Undoubtedly this technique could be 
improved, and much could be gained by the use of molecular techniques to obtain a detailed 
profile, over the period of ventilation, of the gastric microbiome in the ICU patient.  
 
With the advent of culture-independent metagenomic techniques, such as 16S rDNA sequence 
analysis, we have the ability to obtain much more detailed information about the gut microbiota 
in critical illness and the impact of probiotic administration. The probiotic studies to date have 
relied upon culture-based techniques to investigate a complex and dynamic microbial 
community. As these techniques are now more mainstream and readily available, consideration 
should be given to their use in future probiotic studies. Current data suggest that, in health, the 
microbiome of the stomach is dominated by Prevotella, Streptococcus, 





cancer there is a change in this profile with an increase in Firmicutes, 
Streptococcus and Prevotella species. Gastric acid suppression and gastric atrophy enable the 
survival and proliferation of microbes that are normally eradicated by gastric acid.  
 
There is also still much to be learned not only about the relationship between the gut microbiota 
and the host, with the evolving concept of a mutualistic rather than commensal relationship – 
at the centre of which is the manner in which gut bacteria communicate with the host’s immune 
system and participate in a variety of metabolic processes of mutual benefit to the host and the 
microbe (244). 
 
The human, animal and in vitro studies of probiotics carried out to date exhibit a high level of 
heterogeneity in the conditions targeted, models used, and probiotics tested. Furthermore, it is 
likely that we are adopting a simplistic view of the mechanisms of action of the various 
probiotic species, bearing in mind that specific effects may be strain-related. 
 
Even within the studies which appear to demonstrate the beneficial effects of probiotics, there 
is considerable heterogeneity with regard to probiotic species used and dosage, route and timing 
of administration. In future research careful consideration should be given to these factors, as 
well as greater measures to assess the safety of probiotics. 
 
As discussed in section 1.3.1, ventilator care bundles are routinely employed in ICUs 
worldwide and yet adherence to these and variation in implementation have not been accounted 





in terms of VAP prevention. Any further studies should include ventilator care bundles as part 
of the methodology. 
 
Further studies of probiotics in ICU patients should also give consideration to examining their 
immune modulatory effects. Escherichia coli Nissle has previously been shown in other study 
populations to decrease pro-inflammatory cytokines (IL-2, IL-5, IL-6, TNFα, IFNγ) and 
increase IL-10 levels and defensin synthesis. These effects on the host may be relevant to their 
mechanism of action and warrant study in more detail. 
 
Relatively broad exclusion criteria were applied to this study as it involved the novel use of a 
bacterium in a critically ill population. These are in keeping with the criteria employed in the 
study of other probiotics. Although no adverse events relating to the probiotic were 
encountered, in my opinion, more extensive testing in this population would be required before 
relaxing these criteria. 
 
4.4 Conclusion 
Concerns are mounting about multidrug-resistant Gram-negative bacteria and in particular the 
emergence of Enterobacteriaceae with resistance to carbapenems. New antimicrobial agents 
with which to tackle resistant bacteria are in limited supply. The development of new 
antibacterial agents will need to be sustained long term to combat the evolution of resistant 
strains. In the absence of universally effective treatments, preventative strategies such as 






The human, animal and in vitro studies of probiotics carried out to date exhibit a high degree 
of heterogeneity in the conditions targeted, models used, and probiotics tested. These studies 
are likely to reflect an over-simplistic view of the mechanisms of action of probiotic species, as 
any beneficial effects are likely to occur through a variety of mechanisms with different strains 
having specific effects. 
 
These studies have many drawbacks including differences in patient groups and bacteria 
administered; clinical and statistical heterogeneity; study limitations and small sample sizes.  
Hence, there is insufficient evidence from which to draw firm conclusions on the efficacy and 
safety of routine use of probiotics for the prevention of VAP in ICU patients. Furthermore, the 
study of probiotics may have suffered to some extent from the rather extravagant and 
unsubstantiated claims made to promote them commercially. The pseudoscience surrounding 
them may have detracted from their potential use as a scientifically-based, therapeutic option.  
In this study we tested a single probiotic species, E. coli Nissle, which has a clear rationale for 
pathogen displacement. We demonstrated gastric colonisation by this bacterium in a feasible 
and safe way in selected group of ICU patients. A significant reduction in the burden of 
pathogenic Gram-negative bacteria in gastric aspirates after 48 hours was demonstrated in the 
15 ml b.d. treatment group. 
 
We are still far from fully understanding the probiotic-host interaction but given the potential 
benefits that probiotic bacteria have to offer, further study is warranted. Careful consideration 
should be given to appropriately powered studies addressing the questions: which probiotic, by 





In an interesting twist, E. coli Nissle was first isolated in the pre-antibiotic era and used for its 
ability to combat infection. Its use in this area waned with the advent of antibiotics. With the 
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Predominant species E coli
E coli 3.60E+03cfuml-1ECN POS
No yeast
Overall growth 8.40E+03cfuml-1
Predominant species E coli




Predominant species E coli
E coli 1.60E+06cfuml-1ECN POS
No yeast
Overall growth 1.86E+05cfuml-1
Predominant species E coli












































































   
   
   
   
   
   










   
   
   
   
   
   



































E coli 0.00E+00 cfuml-1
V light yeast
Overall growth 1.72E+04 cfuml-1
Predominant species CNS












Overall growth 8.00E+04 cfuml-1
Predominant species CNS

















































































































   
   
   
   
   
   










   
   
   
   
   
   











Overall growth 8.76E+05 cfuml-1
Predominant species Enterococci




Overall growth 4.00E+06 cfuml-1
Predominant species mixed 50:50 
Enterococci: E coli
E coli 1.05E+06 cfuml-1   ECN POS
No yeast
Overall growth 4.00E+05 cfuml-1
Predominant species Enterococci


















Overall growth 1.64E+03 cfuml-1
Predominant species CNS
E coli 0.00E+00 cfuml-1 
Light yeast
Overall growth 1.60E+06 cfuml-1
Predominant species Enterococci
E coli 3.72E+05 cfuml-1ECN POS
Heavy yeast
Overall growth >2000000 cfuml-1
Predominant species E coli










































































Overall growth 3.00E+03 cfuml-1
Predominant species E coli


























































   
   
   
   
   
   










   
   
   
   
   
   













Overall growth 3.14E+05 cfuml-1
Predominant species ? Streps
E coli 1.04E+05 cfuml-1 ECN POS
Medium yeast
Overall growth 3.20E+05 cfuml-1 
Predominant species Mixed CNS 
E coli 0.00E+00 cfuml-1
Heavy yeast
Overall growth 4.00E+06 cfuml-1 
Predominant species E coli
E coli 4.00E+06 cfuml-1   ECN POS
Heavy yeast
Overall growth 2.46E+05 cfuml-1 
Predominant species CNS


















Overall growth 3.72E+05 cfuml-1 
Predominant species E coli
E coli 2.08E+05 cfuml-1   ECN POS
Heavy yeast
Overall growth 1.00E+05 cfuml-1 
Predominant species Mixed CNS/Streps

































































































   
   
   
   
   
   




















Overall growth 1.30E+04 cfuml-1
Predominant species CNS
Heavy yeast


























































































































































   
   












   
   
   
   
   










Predominant species E coli
E coli 1.00E+06cfuml-1ECN POS
Heavy yeast
Overall growth 9.60E+05cfuml-1
Predominant species E coli
E coli 9.60E+05cfuml-1ECN POS
Heavy yeast
Overall growth 2.60E+03 cfuml-1
Predominant species CNS


































































































   
   








   
   
   




   
   
   
   
   










































Predominant species 50:50 E coli:Enterococci
E coli 8.00E+05cfuml-1ECN NEG
Heavy yeast
Overall growth >2000000cfuml-1


























































































   
   
   
   






   
   
   
   
   






























































   
   
   
   
   
   










   
   
   
   
   
   











Overall growth 1.20E+06 cfuml-1
Predominant species 50:50 Enterococci:CNS
Heavy yeast





































































































































   
   
   
   
   
   










   
   
   
   
   
   






































Overall growth 1.46E+05 cfuml-1
Predominant species Enterococci


















































   
   
   
   
   
   










   
   
   
   
   
   

















Overall growth 2.00E+05 cfuml-1
Predominant species Staph
E. Coli 0.00E+00cfu ml-1
No yeast
Overall growth 4.60E+03cfuml-1
Predominant species E coli 



























































































   
   
   
   
   
   










   
   
   
   
   
   













Overall growth 4.00 E+04 cfu ml-1
Predominant species staph/streps
Heavy growth yeast
Overall growth 1.20E+04 cfu ml-1
Predominant species micrococci (23 
colonies cns) 
Light growth yeast 
No growth
Medium growth yeast 
Overall growth 4.86E+03 cfu ml-1
Predominant species staph/streps
Heavy growth yeast






































































Overall growth 6.06E+03 cfu ml-1
Predominant species micrococci (2 
colonies cns)






















































































   
   
   
   
   
   










   
   
   
   
   
   



















Overall growth 6.52E+05 cfuml-1
Predominant species Enterococci
E.Coli 0.00E+00cfuml-1
V Light yeast 
Samples not taken



























































Overall growth  9.06E+04 cfuml-1




Overall growth 1.44E+05 cfuml-1
Predominant species Enterococci
E.Coli 0.00E+00cfuml-1



































































































   
   
   
   
   
   










   
   
   
   
   
   













Overall growth >2000000 cfu ml-1
Predominant species enterococci
E.Coli 0.00E+00 cfu ml-1
V light yeast
Overall growth >2000000 cfu ml-1
Predominant species enterococci/cns
E.Coli 0.00E+00 cfu ml-1
Heavy yeast
Overall growth 1.34E+06 cfu ml-1
Predominant species enterococci
E.Coli 0.00E+00 cfu ml-1
Light yeast
Overall growth 6.46E+05  cfu ml-1
Predominant species enterococci
(Plus staph/strep)
































































Overall growth 9.28E+05 cfu ml-1
Predominant species enterococci
E.Coli 0.00E+00 cfu ml-1
No yeast
Overall growth 1.06E+06  cfu ml-1
Predominant species 
enterococci/staph
E.Coli 0.00E+00 cfu ml-1
Light yeast
Overall growth 1.85E+06 cfu ml-1
Predominant species enterococci  (plus 

























































   
   
   
   
   
   










   
   
   
   
   
   
































































































































































   
   
   
   
   
   










   
   
   
   
   
   



































E.Coli1.20E+05 cfuml-1           ECN POS
Heavyyeast




Overall growth 3.72E+04 cfuml-1
Predominant species CNS/Strep 
E.coli0.00E+00 cfuml-1
Medium yeast





















































































































   
   
   
   
   
   










   
   
   
   
   
   



































Overall growth >2000000 cfuml-1
Predominant species ? Enterococci
E.Coli>2000000 cfuml-1
No yeast


















































   
   
   
   
   
   










   
   
   
   
   
   

























































































































































































   
   
   
   
   
   










   
   
   
   
   
   




















































































































































































































   
   
   
   
   
   


























Overall growth 4.00E+04 cfuml-1
Predominant species ? Streps




Overall growth 1.60E+06 cfuml-1





Overall growth 1.08E+03 cfuml-1






















































































   
   
   
   
   
   










   
   
   
   
   
   














Overall l growth 1.24E+03 cfuml-1



















































































   
   
   
   
   
   










   
   
   
   
   


































Overall growth 1.14E+03 cfuml-1
Predominant species CNS
Light yeast










































   
   
   
   
   
   










   
   
   
   
   
   











Overall growth 7.40E+02 cfuml-1
Predominant species mixed (CNS/Streps)
V light yeast
Overall growth 4.10E+03 cfuml-1





























































































   
   
   
   
   
   










   
   
   
   
   
   













Overall growth 3.14E+05 cfuml-1
Predominant species Coliform (? Klebsiella)
Heavy yeast
Overall growth >2000000 cfuml-1














































































   
   
   
   
   
   










   
   
   
   
   
   



























Overall growth >2000000 cfuml-1
Predominant species E.coli
V light yeast
Overall growth >2000000 cfuml-1
Predominant species Coliform
Medium yeast
Overall growth 1.86E+06 cfuml-1














































































   
   
   
   
   
   










   
   
   
   
   
   


























































































































































































   
   
   
   
   
   










   
   
   
   
   




































































































































   
   
   
   
   
   


















No growth  
E.coli0.00E+00cfuml-1
No yeast
























































































   
   
   
   
   
   










   
   
   
   
   
   

































































































































































   
   
   
   
   
   










   
   
   
   
   
   






























Overall growth >2000000 cfuml-1
Predominant species Entero?cocci
E.Coli1.20E+04 cfuml-1ECN POS (? timing)
Medium yeast


























































































   
   
   
   
   
   










   
   
   
   
   
   













Overall growth >2000000 cfuml-1
Predominant species Enterococci
E.Coli8.40E+04 cfuml-1  ECN POS
No yeast
Overall growth >2000000 cfuml-1
Predominant species Enterococci
E.Coli3.72E+05 cfuml-1  ECN POS
No yeast




Overall growth 8.96E+05 cfuml-1
Predominant species E.coli




































































































   
   
   
   
   
   
























   
   
   






















Overall growth 3.50E+05 cfuml-1
Predominant species E.coli
E.Coli2.68E+05  cfuml-1ECN POS
Light yeast 




Overall growth >2000000 cfuml-1
Predominant species mixed Entercocci/Bacillus
E.Colicfuml-1–unable to quantify ECN POS
V light yeast 
Overall growth >2000000 cfuml-1
Predominant species mixed Enterococci/E.coli
E.Colicfuml-1–unable to quantify & unable to 
isolate to type
Heavy yeast 
Overall growth >2000000 cfuml-1
Predominant species mixed 
Enterococci/Bacillus












































Overall growth >2000000 cfuml-1
Predominant species E.coli
E.Coli>2000000  cfuml-1ECN POS
Medium yeast
Overall growth >2000000 cfuml-1




































































   
   
   
   
   
   










   
   
   
   
   
   







































Ubaleto obtain NG aspirate






























































































Ubaleto obtain NG aspirate

























































































































































   
   
   
   
   











   
   
   
   
   












































































































   
   
   
   
   
   










   
   
   
   
   
   



















Overall growth >2000000 cfuml-1
Predominant species ?micrococci 
E.coli 0.00E+00 cfuml-1
No yeast




Overall growth >2000000 cfuml-1
Predominant species ?micrococci 
E.coli 0.00E+00 cfuml-1
Light yeast
Overall growth >200000 cfuml-1
Predominant species ?micrococci 
E.coli 9.60E+03cfuml-1ECN POS
V light yeast
Overall growth 2.18E+05 cfuml-1
Predominant species E.coli













































Probiotic Escherichia coli Nissle 1917 
(Mutaflor®) Product Information and 





































The original concept for this work was presented at the Intensive Care Society Research 
Prioritisation Exercise in London on the 6th July 2011. 



















